Urine stabilization
The combination of EDTA and polyethylene glycol in urine stabilization methods addresses the degradation issue of cell-free DNA and cells, enabling effective preservation and analysis of urine samples for diagnostic purposes.
Patent Information
- Application Number
- JP2024147355
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-01-04
- Filing Date
- 2024-08-29
- Publication Date
- 2024-12-03
AI Technical Summary
Existing urine stabilization methods fail to effectively preserve cell-free DNA and cells in urine samples, leading to rapid degradation and dilution, which complicates subsequent analysis and diagnostic applications.
A method involving the use of a chelating agent, such as EDTA, combined with a poly(oxyethylene) polymer, preferably polyethylene glycol, to stabilize urine samples, inhibiting bacterial growth and preserving both cell-free DNA and genomic DNA, allowing for simultaneous stabilization of cells and nucleic acids.
The method effectively stabilizes cell-free DNA and genomic DNA in urine samples, enabling multimodality tests and cytological analysis, while preventing bacterial growth and degradation, allowing for prolonged storage at room temperature without significant quality loss.
Smart Images

Figure 2024167329000010 
Figure 2024167329000011 
Figure 2024167329000012
Abstract
Description
[Technical field]
[0001] FIELD OF THEINVENTION The present invention provides methods, compositions and collection containers for stabilizing urine samples. The techniques of the present invention allow for the simultaneous stabilization of cell-free and genomic DNA, as well as the stabilization of cells in urine. [Background technology]
[0002] 2. Background of the Invention Although most of the DNA in the body is located inside cells, small amounts of nucleic acids can also be found circulating freely in human body fluids such as blood and urine (usually referred to as extracellular DNA, cell-free DNA or circulating DNA).The presence of elevated levels of extracellular DNA and other extracellular nucleic acids in many medical conditions, malignant diseases and infectious processes is of interest, among others, for screening, diagnosis, prognosis, monitoring of disease progression, for identifying potential therapeutic targets, and for monitoring treatment response.
[0003] Depending on the sample type, degradation of extracellular DNA in bodily fluid samples is also an issue, as is the potential dilution of the extracellular DNA with genetic material from damaged or disintegrating cells after sample collection.
[0004] To avoid or reduce the above problems, it is recommended to obtain plasma from whole blood immediately after blood collection and / or to stabilize blood samples until plasma is obtained. Meanwhile, the stabilization and isolation of extracellular DNA from blood samples is well established. For the stabilization of blood samples, some dedicated blood collection tubes are commercially available (Streck, Roche, PreAnalytiX, Biomatrica, Norgene, etc.). Stabilization methods are described, for example, in WO2013 / 045457, WO2013 / 045458, WO2014 / 146780, WO2014 / 146782, WO2014 / 146781, WO2014 / 049022 and WO2017 / 085321.
[0005] Although it is much less invasive than biopsy collection, blood sampling is still invasive and may be difficult or impossible, especially for elderly, young children, or cancer patients undergoing treatment.A truly non-invasive sample as an alternative source for treatment monitoring, resistance failure testing, or further diagnosis would be a valuable complement to current liquid biopsy techniques.Now, cell-free DNA purification from urine provides a simple and completely non-invasive alternative.
[0006] This urine can be used as liquid biopsy has been shown in many peer-reviewed publications, in addition to conventional cytohistological analysis, i.e., conventional cytohistological analysis of urothelial carcinoma, gDNA and cell-free DNA from cancer or malignant cells in urine has been associated with cancer-specific sequence alterations, epigenetic alterations, and structural alterations. The results of this study have been published in 117 patients with bladder cancer (Birkenkamp-Demtroder K et al. Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer. Eur Urol. 2016 Jul;70(1):75-82), prostate cancer (Salvi S et al. Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients. Dis Markers. 2015;2015:574120), lung cancer (Chen S, Zhao J, Cui L, Liu Y. Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs. Clin Transl Oncol. 2017 Mar;19(3):332-340) and other solid tumor cancer types (Fujii T et al. Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from It has been published that urine from patients with advanced cancers. Clin Cancer Res. 2017 Jul 15;23(14):3657-3666) contains cell-free DNA from tumors. Furthermore, isolation of fetal DNA from urine samples has been described. Therefore, besides blood, urine is also an important liquid biopsy sample.
[0007] However, both nucleated cells and cell-free DNA in urine are unstable and dissolve or degrade rapidly during urine sample collection. In addition, exfoliated nucleated cells such as normal epithelial cells or cancer-derived cells in urine release genomic DNA and dilute cell-free DNA. DNA degradation is particularly rapid in urine and occurs essentially immediately after sample collection. Therefore, an efficient stabilization method is needed to preserve cell-free DNA in urine by reducing the degradation of contained cell-free DNA during storage. In this regard, it should be noted that the efficient preservation of cell-free DNA contained in the original urine sample is difficult to determine based on the total amount of cell-free DNA contained in the urine sample after storage. This is because the originally present cell-free DNA that is degraded during storage may be replenished with DNA released from cells contained in the urine sample. Thus, even if the total amount of DNA in the cell-free urine fraction is the same after storage as during urine sample collection, the originally present cell-free DNA may nevertheless be degraded, and the DNA contained in the cell-free urine fraction after storage may essentially represent the DNA released from cells during storage. However, it is the cell-free DNA originally present in the cell-free urine fraction that is particularly valuable analytically, and not the DNA released from cells into the cell-free liquid urine fraction during storage. If the cell-free DNA originally present is degraded during storage, it cannot be used for subsequent analysis. Therefore, the important purpose of urine stabilization is to stabilize the cell-free DNA contained in urine at the time of sample collection. Furthermore, it is desirable to achieve the stabilization of the cells contained by urine stabilization techniques, so that the cells can be recovered from the stabilized urine sample for further applications, such as cell histological examination methods and / or the isolation of genomic DNA from the cells. Known urine stabilization methods do not adequately address these objectives.
[0008] One known urine stabilization method (Streck's urine cell-free DNA preservative) is based on the use of a formaldehyde-releasing agent. The urine cell-free DNA preservative is provided in a 5 ml vial. The reagent from one vial must be mixed with 25 to 100 ml of urine. This approach has several disadvantages. It requires that unstabilized urine be brought to the laboratory or clinic, thereby delaying the time point at which the urine is stabilized. Furthermore, for stabilization, the initial collection cup must be in an open state and the stabilizing reagent must be added from the vial and mixed with the urine. These manual operations are inconvenient and error-prone. Furthermore, reagents containing formaldehyde have the disadvantages of being toxic and chemically modifying biomolecules such as proteins and nucleic acids. This may reduce the amount of cell-free DNA that can be recovered and therefore analyzed. This is a major disadvantage as it may limit the number of cell-free DNA of interest in the urine sample.
[0009] Trovagene has a reagent (NextCollect) that stabilizes cell-free DNA in urine according to the manufacturer. It has integrated this reagent into the cup of the urine collection container. Zymo and Norgen offer reagents that preserve urine for subsequent use in total DNA. However, it is not possible to analyze genomic DNA and cell-free DNA separately.
[0010] Additionally, several other urine collection devices are known in the art. For example, Becton Dickenson (BD) offers a product line for transferring urine into a vacutainer. The BD Vacutainer® urine collection cup is a collection container with a cup that includes a needle for transferring urine into a vacutainer without the need to open the cup. The BD Vacutainer® urine collection straw is a device for transferring urine from any container to a vacutainer. One end of the device is placed in the urine and the other end includes a needle that can be attached to the vacutainer. The BD Vacutainer® Urinary Preservative Tubes are tubes that contain a spray-dried bacterial preservative intended to be used with urine, either a vacutainer with a draw volume of 8 ml or no additive and a draw volume of 8 to 10 ml. DNA is not preserved by any of these vacutainers.
[0011] Therefore, there is a need for improved methods that allow efficient stabilization of urine samples as liquid biopsy samples, which should allow the subsequent isolation of cell-free DNA and cells contained in the urine sample.
[0012] Therefore, it is an object of the present invention to provide a means for stabilizing urine samples.In particular, it is an object of the present invention to overcome at least one of the shortcomings of the prior art urine stabilization methods.Furthermore, it is an object of the present invention to provide a stabilization technique that allows the subsequent recovery of cell-free DNA and / or intracellular DNA, such as genomic DNA, and further allows the cytological analysis of the stabilized cells. [Prior art documents] [Patent documents]
[0013] [Patent Document 1] International Publication No. 2013 / 045457 [Patent Document 2] International Publication No. 2013 / 045458 [Patent Document 3] International Publication No. 2014 / 146780 [Non-patent literature]
[0014] [Non-Patent Document 1] Birkenkamp-Demtroder K et al. Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer. Eur Urol. 2016 Jul;70(1):75-82 [Non-Patent Document 2] Salvi S et al. Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients. Dis Markers. 2015;2015:574120 [Non-Patent Document 3] Chen S, Zhao J, Cui L, Liu Y. Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients with EGFR-TKIs. Clin Transl Oncol. 2017 Mar;19(3):332-340 Summary of the Invention [Means for solving the problem]
[0015] The present invention provides an effective stabilization technique for urine samples that preserves extracellular DNA (also referred to herein as cell-free DNA) as well as intracellular nucleic acids such as contained cellular and genomic DNA. The provided stabilization technique allows, in particular, the degradation of cell-free DNA in urine samples and the inhibition of bacterial growth. Thus, the stabilization technique of the present invention stabilizes the cell-free DNA in urine as well as the genomic DNA and cytological properties of cells found in urine. Thereby, the present invention provides a solution for the simultaneous stabilization of cell-free DNA and genomic DNA and the stabilization of cells in urine. Thereby, multimodality testing, including cell-free DNA testing and genomic DNA testing as well as conventional cytological staining, is possible for urine samples stabilized using the technique according to the present invention.
[0016] Furthermore, the present invention provides a sample collection, stabilization and preparation system for urine. The stabilization chemistry of the present invention may be contained within a urine receiving container, preferably a vacuum tube, which may be used in combination with established urine collection containers and established nucleic acid purification and assay techniques. Thereby, the present invention also provides a standard system for molecular analysis from urine samples, including the entire workflow from urine collection to insight nucleic acid analysis and / or cellular analysis.
[0017] According to a first aspect, there is provided a method for stabilizing a urine sample, comprising the steps of contacting the urine sample with a chelating agent, preferably EDTA, and at least one poly(oxyethylene) polymer, preferably polyethylene glycol, for stabilization, wherein bacterial growth is inhibited in the stabilized urine sample. Preferably, the compound used for stabilization is comprised in a stabilizing composition, such as the stabilizing composition according to the third aspect.
[0018] According to a second aspect, there is provided a method for processing a urine sample, comprising the steps of: a) stabilizing a urine sample according to the method of the first aspect, and b) isolating cells from the stabilized urine sample, thereby providing (i) a cell sample and (ii) a cell-depleted supernatant. A method is provided, comprising:
[0019] According to a third aspect, there is provided a stabilizing composition for stabilizing a urine sample, the composition comprising: a chelating agent, preferably EDTA, at least one poly(oxyethylene) polymer, preferably polyethylene glycol, and optionally - A preservative to inhibit bacterial growth A stabilized composition is provided comprising:
[0020] Each stabilizing composition allows the stabilized urine sample to be stored and / or handled, e.g., transported, at room temperature for many days without substantial loss of sample quality. The stabilizing compositions may be part of a closed urine collection system that is easy to handle, safe, and does not require manual manipulation.
[0021] According to a fourth aspect, the present invention relates to the use of a stabilising composition according to the third aspect for stabilising a urine sample. The stabilising composition according to the third aspect may for example be used for stabilisation in a method according to the first aspect.
[0022] According to a fifth aspect, there is provided a receiving device for receiving a urine sample, comprising: a chelating agent, preferably EDTA, at least one poly(oxyethylene) polymer, preferably polyethylene glycol, and - Optionally, a preservative to inhibit bacterial growth A receiving device is provided, comprising:
[0023] The receiving device is suitable for stabilizing a urine sample. Bacterial growth may be inhibited in the stabilized urine sample. The receiving device according to this is preferably a vacuum collection tube and preferably comprises a stabilizing composition according to the third aspect, such as a stabilizing composition as defined in any one of claims 18 to 24. Providing such a respective receiving device has the advantage that the urine sample is stabilized immediately when the sample is contained in the respective device. The receiving device may be used for stabilization in the method according to the first aspect.
[0024] According to a sixth aspect there is provided a method comprising the step of collecting a urine sample. According to one embodiment the urine sample is collected in a chamber of a device according to the fifth aspect of the invention. According to a further embodiment the method for collecting a urine sample comprises: a) collecting urine in a container, preferably a urine cup; and b) stabilising the urine sample using the method according to the first aspect Includes.
[0025] The urine collected in step a) may be transferred into a receiving device according to the fifth aspect for stabilisation in step b), wherein the receiving device preferably comprises a stabilising composition according to the third aspect, such as a stabilising composition as defined in any one of claims 18 to 24.
[0026] According to a seventh aspect, there is provided a method for producing a composition according to the third aspect of the invention, wherein the components of the stabilized composition are preferably combined in a liquid composition, such as a solution. The term "solution" as used herein refers in particular to a liquid composition, preferably an aqueous composition. This may be a homogeneous mixture of only one phase, but it is also within the scope of the invention that the solution contains solid components, such as, for example, a precipitate.
[0027] Other objects, features, advantages and aspects of the present application will become apparent to those skilled in the art from the following description and appended claims. It should be understood, however, that the following description, appended claims, and specific examples, while indicating preferred embodiments of the present application, are given by way of illustration only. [Brief description of the drawings]
[0028] [Figure 1] FIG. 1 shows the stabilization of cell-free DNA in urine. The average Ct values of 18s rDNA 66bp fragment by qPCR from six donors are shown with standard deviation. Urine was mixed with 1.7 ml of phosphate-buffered saline (PBS) or stabilization reagent according to the present disclosure. DNA was isolated from cell-depleted urine samples processed immediately (t0, left column) or after 4 days of storage at RT (right column).
[0029] [Diagram 2] Figure 2 shows the stabilization of large DNA in urine. The average Ct values of 18s rDNA 500bp fragments by qPCR from six donors are shown with standard deviation. Urine was mixed with 1.7 ml of phosphate-buffered saline (PBS) or the stabilization reagent according to the present disclosure. DNA was isolated from cell-depleted urine samples immediately (t0, left column) or after 4 days of storage at RT (right column).
[0030] [Diagram 3]Figure 3 shows cell-free DNA in urine collected directly from the BD Vacutainer Urine Collection Cup into vacutainers. The increase in copy number of the 18s rDNA 66bp fragment after storage relative to t0 as determined by qPCR from four donors (two females and two males) is shown with standard deviation. Urine was collected into BD Vacutainer collection cups and transferred into different vacutainers. For stabilization with R1, urine was transferred into spray-dried K2-EDTA tubes, after which 1.7 ml of R1 reagent was added. Cell-free DNA was isolated from cell-depleted urine samples immediately or after storage at RT for 1 day (left column), 3 days (middle column) and 9 days (right column).
[0031] [Figure 4] Figure 4 shows the preservation of cell-free DNA from male urine spiked into female urine collected in vacutainers from a BD Vacutainer Urine Collection Cup. The average delta Ct values (DYS14 qPCR, two female donors) between samples stored at RT and samples processed at time point t0 are shown. Cell-free DNA was isolated immediately or after 1 day (left column), 3 days (middle column) and 9 days (right column) of storage at RT. Lower delta-Ct values indicate better preservation of cell-free DNA contained in the urine samples.
[0032] [Diagram 5] Figure 5 shows the stabilization of cell-free DNA in urine used for multimodality testing. The mean Ct values of the 18s rDNA 66 fragment (Figure 5a) and 500 bp fragment (Figure 5b) by qPCR from duplicate sample preparations and triplicate PCRs of three donors are shown with standard deviations. Urine was either destabilized or mixed with 1.7 ml of reagent R1 after collection. Cell-free DNA was isolated from urine samples processed immediately after collection (t0, left column) or after storage at RT for 3 days (middle column) and 7 days (right column).
[0033] [Figure 6]Figure 6 shows the stabilization of genomic DNA from urine cells in a multimodality testing setting. The average yield from 2 / 3 of the cell pellets from three different donors was measured with TapeStation (Figure 6a) and visualized on an agarose gel (Figure 6b). Urine was either destabilized or mixed with 1.7 ml of reagent R1 after collection. gDNA was isolated from the cell pellets obtained by centrifugation immediately after collection (t0, left column) or after storage at RT for 3 days (middle column) and 7 days (right column).
[0034] [Figure 7] Figure 7 shows the stabilization of cytological properties of cells from urine samples in a multimodality test setting. Urine was either not stabilized or mixed with 1.7 ml of reagent R1 after collection. Cells from cell pellets obtained by a single centrifugation immediately after collection (t0) or after 7 days of storage at RT were centrifuged onto glass slides, air-dried and stained with Papanicolaou.
[0035] [Figure 8] FIG. 8 shows the effect of pH on cell-free DNA storage as demonstrated based on DYS14 DNA from males spiked into female urine. The average DYS14 qPCR Ct values from six female donors are shown with standard deviation. Female urine was used either pure (Unstab.) or mixed with 1.7 ml of phosphate buffered saline (PBS) or various stabilizing reagents according to the present disclosure. Cell-free DNA was isolated immediately (t0, left column) or after storage at RT for 4 days (right column).
[0036] [Figure 9] FIG. 9 shows the stabilization of cell-free DNA urine using the stabilization reagent according to the present invention. The average Ct value of 18S rDNA 66bp fragment by qPCR from six donors is shown with the standard deviation. Urine was mixed with 1.7 ml of phosphate buffered saline (PBS) or the stabilization reagent according to the present invention set at various pH values. Cell-free DNA was isolated immediately after urine processing (t0) or after storage for 4 days (t4d) or 7 days (t7d).
[0037] [Figure 10] Figure 10 shows the stabilization of large cell-free DNA in urine using the reagent according to the invention. The average Ct values of 18S rDNA 500bp fragments by qPCR from six donors are shown with standard deviation. Urine was mixed with 1.7 ml of phosphate buffered saline (PBS) or with the stabilizing reagent according to the invention at various pH values. Cell-free DNA was isolated from treated urine immediately (t0), after storage for 4 days (t4d) or 7 days (t7d).
[0038] [Figure 11] Figure 11 shows the stabilization of genomic DNA from urine cells. Urine was stabilized with 1.7 ml of the stabilization reagent according to the invention at various pH values. gDNA was isolated from the cell pellet obtained by centrifugation either immediately after collection (t0) or after storage at room temperature for 7 days (t7d).
[0039] [Figure 12] Figure 12 shows the effect of pH on the preservation of cell-free male-derived DYS14 DNA in female urine. The average DYS14 qPCR Ct values from four female donors are shown with standard deviation. Female urine was mixed with 1.7 ml of phosphate buffered saline (PBS) or stabilizing reagent according to the invention at various pH values. Cell-free DNA was isolated immediately (t0) or after storage at RT for 4 days (t4d) or 7 days (t7d).
[0040] [Figure 13]Figure 13 shows the effect of pH on the preservation of cell-free male-derived DYS14 DNA in urine. DYS14 qPCR Ct values from four female and two male donors are shown. Urine was mixed with 1.7 ml of phosphate-buffered saline (PBS) or with the stabilizing reagent of the present invention set at various pH values. Cell-free DNA was isolated immediately (t0) or after 4 days (t4d) or 7 days (t7d) of storage at RT. Male donors (donors 5 and 6) show an increase in DYS14 DNA in cfDNA over time when using the reagent of the present invention with neutral or basic pH.
[0041] [Figure 14] Figure 14 shows the stabilization of small DNA in cell-free urine using the reagent according to the invention. The average Ct values of 18S rDNA 66bp fragments by qPCR from six donors are shown with standard deviation. Urine was mixed with 1.7 ml of phosphate buffered saline (PBS) or with the stabilizing reagent according to the invention at various pH values. Cell-free DNA was isolated immediately (t0) or after storage for 4 days (t4d).
[0042] [Figure 15] Figure 15 shows the stabilization of large DNA in cell-free urine using the reagent according to the invention. The average Ct values of 18S rDNA 500bp fragments by qPCR from six donors are shown with standard deviation. Urine was mixed with 1.7 ml of the stabilizing reagent according to the invention set at various pH values. Cell-free DNA was isolated immediately (t0) or after storage for 4 days (t4d).
[0043] [Figure 16] Figure 16 shows the effect of pH on the preservation of cell-free male-derived DYS14 DNA in female urine. The average DYS14 qPCR Ct values from six female donors are shown with standard deviation. Female urine was mixed with 1.7 ml of stabilizing reagent according to the invention set at various pH values. Cell-free DNA was isolated immediately (t0) or after storage at RT for 4 days (t4d). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0044] Detailed Description of the Invention Various aspects of the disclosure will now be described in further detail. A. Stabilization Methods
[0045] According to a first aspect there is provided a method for stabilising a urine sample, comprising the steps of contacting the urine sample with a chelating agent, preferably EDTA, and at least one poly(oxyethylene) polymer, preferably polyethylene glycol, for stabilisation, wherein bacterial growth is inhibited in the stabilized urine sample. Details of the method according to the first aspect are also defined in claims 1 to 15.
[0046] Details of the compounds used for stabilization and further stabilizing agents that can be used to stabilize the urine sample are disclosed below. As disclosed herein, the compounds used for stabilization are preferably included in a stabilizing composition that is contacted with the urine sample. Preferably, the stabilizing composition according to the third aspect is used to stabilize the urine sample. Chelating Agents
[0047] Urine stabilization according to the present invention involves the use of a chelating agent, preferably ethylenediaminetetraacetic acid (EDTA). A chelating agent is an organic compound capable of forming a coordinate bond with a metal by two or more atoms of the organic compound. Chelating agents according to the present invention include, but are not limited to, ethylenedinitrilotetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), ethyleneglycoltetraacetic acid (EGTA) and N,N-bis(carboxymethyl)glycine (NTA), as well as, for example, citrate or oxalate. Other chelating agents include, but are not limited to, salts of carboxylic acids, such as citrate or oxalate, and any combination thereof.
[0048] According to a preferred embodiment, EDTA is used as chelating agent.All disclosures and embodiments described in this application regarding chelating agent in general specifically apply and, unless expressly stated, refer to EDTA, which is a preferred embodiment.As used herein, the term "EDTA" refers to the EDTA part of EDTA compound, such as K2EDTA, K3EDTA or Na2EDTA, among others.
[0049] The use of a chelating agent such as EDTA has the advantageous effect of inhibiting nucleases such as DNase and RNase, thereby reducing the degradation of cell-free DNA contained in the urine sample by nucleases. Therefore, the use of a chelating agent such as EDTA to stabilize the urine sample is highly advantageous.
[0050] According to one embodiment, the final concentration of the chelating agent, preferably EDTA, in the stabilized urine sample, and thus in the mixture obtained when the urine sample is contacted with the chelating agent, the poly(oxyethylene) polymer, the preservative and, if necessary, one or more additional additives, is in the range of 0.9 mg / ml to 40 mg / ml, such as 2 mg / ml to 40 mg / ml. Exemplary and preferred ranges are disclosed below, and the ranges disclosed are particularly suitable for using EDTA as the chelating agent. The final concentration in the stabilized urine sample may be at least 4 mg / ml, at least 5 mg / ml or at least 7 mg / ml. Using a higher concentration of the chelating agent, such as preferably EDTA, to stabilize urine is advantageous to achieve a strong stabilizing effect. Thus, in an embodiment, the final concentration of the chelating agent, preferably EDTA, in the stabilized urine sample is at least 7 mg / ml, preferably at least 10 mg / ml. In the examples, a concentration of at least 15 mg / ml was used. According to one embodiment, the final concentration of the chelating agent, preferably EDTA, is in the range of 10 mg / ml to 35 mg / ml or 10 mg / ml to 30 mg / ml. Final concentrations in the range of 12 mg / ml to 30 mg / ml or 15 mg / ml to 25 mg / ml are also suitable. In the examples, EDTA was used in a final concentration in the stabilized urine in the range of 15 mg / ml to 20 mg / ml.
[0051] According to one embodiment, a chelating agent such as EDTA is included in the stabilizing composition which is contacted with the urine sample for stabilization. Preferably, a stabilizing composition according to the third aspect is used for this purpose.
[0052] However, chelating agents such as EDTA alone do not achieve sufficient stabilizing effect for the purposes described herein, as demonstrated in the Examples, and are therefore used in combination with additional stabilizing agents as described herein. Poly(oxyethylene) polymers, preferably polyethylene glycol
[0053] Urine stabilization according to the present invention further involves the use of at least one poly(oxyethylene) polymer as a stabilizing agent. The term poly(oxyethylene) polymer refers in particular to an oligomer or polymer of ethylene oxide. It contains at least two ethylene oxide units. Poly(oxyethylene) polymers are known in low and high molecular weights. Their molecular weights are usually multiples of 44, the molecular weight of its monomer, and can range up to 100,000. Molecular weights are given in Da herein. Poly(oxyethylene) polymers can be linear or branched, or have other geometric shapes. Linear poly(oxyethylene) polymers are preferred. Poly(oxyethylene) polymers can be unsubstituted or substituted, and are preferably polyethylene glycol. Polyethylene glycol has a stabilizing effect on cells at various molecular weights and various concentrations, and can therefore be used to stabilize urine samples. However, other poly(oxyethylene) polymers that achieve the stabilizing effect as achieved by polyethylene glycol can also be used. As mentioned, poly(oxyethylene) esters, poly(oxyethylene) amines, poly(oxyethylene) thiol compounds, poly(oxyethylene) glycerides, and the like can be used, as well as substituted poly(oxyethylene) polymers having a stabilizing effect, such as alkyl poly(oxyethylene) polymers, e.g., alkyl polyethylene glycols.
[0054] As poly(oxyethylene) polymer for urine stabilization, polyethylene glycol is preferably used. The polyethylene glycol is preferably unbranched and may be unsubstituted or substituted. Known substitution forms of polyethylene glycol include, for example, alkylpolyethylene glycol substituted at one or both ends with C1-C5 alkyl groups. Most preferably, the polyethylene glycol has the formula HO-(CH2CH2O) nAll disclosures and embodiments set forth in this application regarding poly(oxyethylene) polymers in general apply specifically and, unless expressly stated otherwise, refer to the preferred embodiment polyethylene glycol, specifically unsubstituted polyethylene glycol.
[0055] Poly(oxyethylene) polymers of various molecular weights can be used. It has been found that poly(oxyethylene) polymers of higher molecular weight are more effective stabilizers than poly(oxyethylene) polymers of lower molecular weight. In order to achieve efficient stabilization with poly(oxyethylene) polymers of lower molecular weight, it is generally recommended to use higher concentrations in comparison. However, in some applications, it is preferable to keep the amount of additives used for stabilization low. Therefore, in embodiments, high molecular weight poly(oxyethylene) polymers are contacted with urine sample for stabilization, since high molecular weight poly(oxyethylene) polymers can achieve a strong stabilizing effect while allowing the use of lower concentrations of poly(oxyethylene) polymers.
[0056] Thus, according to one embodiment, a high molecular weight poly(oxyethylene) polymer having a molecular weight of at least 1500 is used as a stabilizer and contacted with a urine sample. The high molecular weight poly(oxyethylene) polymer may have a molecular weight in a range selected from 1500 to 40000. Suitable ranges include 2000 to 35000, 2500 to 30000, 3000 to 25000, 3500 to 20000 and 4000 to 15000. A range of 5000 to 20000, for example 5000 to 15000 or 6000 to 10000, is preferred. For the use of polyethylene glycol, especially unsubstituted polyethylene glycol, these molecular weights are particularly preferred. Unsubstituted polyethylene glycol was also used in the examples. The molecular weight of a poly(oxyethylene) polymer having a specific molecular weight may vary within a specific range depending on the manufacturing conditions, as is well known to those skilled in the art.
[0057] The high molecular weight poly(oxyethylene) polymer is used at a concentration that exerts or supports the stabilization of the urine sample. The suitable concentration can be determined by a person skilled in the art, for example, by testing various concentrations of the specific high molecular weight poly(oxyethylene) polymer in the test assay described in the examples. The stabilization effect achieved and the preferred concentration can vary depending on whether one or more additional stabilizing agents are used. A preferred combination is described herein. According to one embodiment, the mixture obtained after contacting the urine sample with the high molecular weight poly(oxyethylene) polymer and, if necessary, with further additives comprises a final concentration of the high molecular weight poly(oxyethylene) polymer in the range of 0.05% to 8% (w / v). Exemplary suitable ranges for the final concentration in the stabilized urine sample include 0.1% to 4% (w / v), 0.2% to 3% (w / v), 0.25% to 2.5% (w / v) and 0.3% to 2% (w / v). According to one embodiment, the high molecular weight poly(oxyethylene) polymer is used in a lower concentration range, such as 0.2% to 1.5% (w / v), 0.25% to 1.25% (w / v), 0.3% to 1% (w / v) or 0.4% to 0.75% (w / v). It may be advantageous in certain embodiments to use a high molecular weight poly(oxyethylene) polymer at a concentration of 1.25% (w / v) or less or 1% (w / v) or less, especially 0.75% (w / v) or less. Downstream processing, especially purification of cell-free DNA from cell-free supernatant, may be improved. It is advantageous to use a stabilization technique that is compatible with most standard nucleic acid isolation methods.
[0058] According to one embodiment, the poly(oxyethylene) polymer (preferably polyethylene glycol) used for stabilization has a molecular weight of less than 1500, and may be a low molecular weight poly(oxyethylene) polymer having a molecular weight of 1000 or less. It is used at a concentration that can support the urine sample stabilization effect. The suitable concentration for various sample types can be determined by the skilled artisan by testing various concentrations, for example, in the test assay described in the examples. Each poly(oxyethylene) polymer, such as a low molecular weight poly(oxyethylene) polymer having a molecular weight of 1000 or less, can be present at a final concentration in the range of 0.5% to 10% in the mixture obtained after contacting the urine sample with said poly(oxyethylene) polymer and, if necessary, with further additives. Exemplary ranges include 1.5% to 9%, 2% to 8%, 2% to 7%, 2.5% to 7% and preferably 3% to 6%. The percentage values refer to (w / v) when the poly(oxyethylene) polymer is solid, and refer to (v / v) when the poly(oxyethylene) polymer is liquid. The low molecular weight poly(oxyethylene) polymer may have a molecular weight in a range selected from 100 to 1000, 150 to 800 and 150 to 700. Preferably, the molecular weight is in the range of 200 to 600, more preferably 200 to 500, e.g., 200 to 400.
[0059] As described herein, at least two poly(oxyethylene) polymers with different molecular weights can be used for stabilization. They may be of the same type, and preferably both are polyethylene glycol, e.g., preferably unsubstituted polyethylene glycol. According to one embodiment, the difference in molecular weight is at least 500, at least 750, or at least 1000. According to one embodiment, the difference in molecular weight is at least 2500, at least 3500, or at least 5000. It is advantageous to use two poly(oxyethylene) polymers with different molecular weights. The stabilization effect of poly(oxyethylene) polymers seems to vary depending on their molecular weight. It has been found that high molecular weight polymers provide better stabilization efficiency. This embodiment in which at least two poly(oxyethylene) polymers with different molecular weights are used for stabilization is advantageous, since it is possible to provide a balanced composition of poly(oxyethylene) polymers with the desired characteristics regarding the stabilization effect to be achieved and the characteristics required for a particular downstream use, e.g., the purification of cell-free DNA from a stabilized urine sample depleted of cells.
[0060] According to one embodiment, a high molecular weight poly(oxyethylene) polymer as defined above, having a molecular weight of at least 1500, preferably 5000 to 20000, for example in the range of 5000 to 15000, is used in combination with a low molecular weight poly(oxyethylene) polymer having a molecular weight of 1000 or less, preferably in the range of 200 to 600, and the urine sample is contacted with both types of poly(oxyethylene) polymer. A preferred embodiment is described herein. The use of a high molecular weight poly(oxyethylene) polymer in combination with a low molecular weight poly(oxyethylene) polymer is advantageous, since the low molecular weight poly(oxyethylene) polymer can reduce the concentration of high molecular weight poly(oxyethylene) polymer required to achieve effective stabilization of the urine sample. This embodiment is advantageous, since it allows more freedom in terms of the volume or amount of the stabilization composition that can be used. Therefore, the use of a combination of a high molecular weight poly(oxyethylene) polymer and a low molecular weight poly(oxyethylene) polymer to stabilize the extracellular nucleic acid population in a urine sample is a preferred embodiment. The low molecular weight poly(oxyethylene) polymer may be of the same type as the high molecular weight poly(oxyethylene) polymer described above and is preferably a polyethylene glycol, e.g., an unsubstituted polyethylene glycol. Suitable and preferred concentrations and concentration ranges for the high molecular weight poly(oxyethylene) polymer and the low molecular weight poly(oxyethylene) polymer are described above and may be used in embodiments in which both types of polymers are used in combination.
[0061] According to one embodiment, the mixture obtained after contacting the urine sample with the high molecular weight poly(oxyethylene) polymer and the low molecular weight poly(oxyethylene) polymer and, if necessary, with further additives used for stabilization, comprises a high molecular weight poly(oxyethylene) polymer, which may have, for example, a molecular weight in the range of 4000 to 20000, at a final concentration in the range of 0.15% to 1.5%, for example 0.2% to 1% (w / v), preferably 0.25% to 0.75% (w / v), for example 0.5% (w / v), and a low molecular weight poly(oxyethylene) polymer, preferably with a molecular weight in the range of 200 to 800, preferably 200 to 600, at a final concentration in the range selected from 1.5% to 8%, preferably 2% to 7%, more preferably 2.5% to 6%. Polyethylene glycol, preferably unsubstituted polyethylene glycol, is preferably used as the high molecular weight poly(oxyethylene) polymer and as the low molecular weight poly(oxyethylene) polymer. Suitable embodiments relating to the high and low molecular weight poly(oxyethylene) polymers are also described above and in conjunction with the different aspects and embodiments.
[0062] According to one embodiment, the poly(oxyethylene) polymer(s) are included in a stabilizing composition which is contacted with the urine sample for stabilization. Preferably, a stabilizing composition according to the third aspect is used for this. Inhibition of bacterial growth
[0063] The method further achieves that bacterial growth is inhibited in the stabilized urine sample. The bacterial load in the urine sample can vary from high load to almost sterile. Bacteria grow rapidly in urine. Therefore, it is advantageous to efficiently inhibit their growth, since this improves the stabilization effect and the quality of the recovered nucleic acid. Bacteria internalize and digest DNA. Bacteria are a source of enzymes that degrade nucleic acids, such as DNase and also RNase. Therefore, inhibiting bacterial growth in the stabilized urine sample supports the prevention of nucleic acid degradation by such mechanisms. This further reduces the risk that bacterial DNA will be co-purified from the sample and interfere with downstream assays, such as sequencing applications or PCR.
[0064] Chelating agents such as EDTA can achieve bacteriostatic effects at higher concentrations. In order to achieve inhibition of cell growth in the stabilized urine sample, the chelating agent, preferably EDTA, can be used at such high concentrations. Suitable high concentrations are described above. Alternatively or preferably in addition, for stabilization, the urine sample can be contacted with a preservative for inhibiting bacterial growth. If such a preservative is used in addition to the chelating agent, which is preferably EDTA, the preservative is therefore different from the chelating agent used.
[0065] According to one embodiment, the method thus comprises a step of further contacting the urine sample with a preservative for inhibiting bacterial growth for stabilization. The preservative may be an antimicrobial agent, preferably having antimicrobial and, if necessary, antifungal activity. The preservative may comprise or consist of a chemical compound. The preservative may also comprise or consist of two or more compounds that inhibit cell growth. The preservative is used at a concentration such that cell growth is inhibited in the stabilized urine sample. The suitable concentration can be determined by the skilled person for each preservative. The final concentration of the preservative in the stabilized urine may be, for example, within the range of 0.01 to 0.7% w / v, for example 0.03 to 0.5% w / v, or within the range of 0.01 to 0.7% v / v, for example 0.03 to 0.5% v / v.
[0066] According to one embodiment, the preservative may comprise or consist of sodium azide. As demonstrated by the examples, sodium azide is particularly suitable. Sodium azide may be used in the stabilized urine sample at a final concentration of, for example, 0.01% to 0.5% (w / v). According to an embodiment, the final concentration of sodium azide in the stabilized urine sample is within the range of 0.02% to 0.4% (w / v), for example 0.03% to 0.35% (w / v) or 0.04% to 0.3% (w / v).
[0067] Furthermore, the preservative may comprise or consist of at least one isothiazolinone compound, preferably methylchloroisothiazolinone and / or methylisothiazolinone. These compounds may be mixed in a ratio of 3:1. A commercially available preservative for inhibiting bacterial growth that comprises an isothiazolinone compound is ProClin300. As demonstrated by the examples, the preservative is suitable for use in stabilizing urine. The preservative may be used in the stabilized urine sample at a final concentration of, for example, 0.03% to 0.1% (v / v), for example, 0.05% (v / v).
[0068] Further examples of preservatives that may be used include, but are not limited to, chlorhexidine or sodium borate. Additional preservatives and useful concentrations for inhibiting bacterial growth can be determined by one of skill in the art following the disclosure of the present application.
[0069] According to one embodiment, a preservative for inhibiting bacterial growth is included in the stabilizing composition that is contacted with the urine sample for stabilization. Preferably, a stabilizing composition according to the third aspect is used for this. pH
[0070] The agent used for urine stabilization is preferably included in the stabilization composition, for example the stabilization composition according to the third aspect. As demonstrated in the examples, pH influences the stabilization result. The stabilization composition can be used to adjust the pH of the stabilized urine sample. Thereby, it can be achieved that the pH of the stabilized urine sample is within a certain pH range. For this purpose, the stabilization composition that contacts the urine sample for stabilization preferably includes a buffering agent.
[0071] According to one embodiment, the stabilizing composition contacted with the urine sample has a pH in the range of 4.5 to 9.5. Preferably, the pH of the stabilizing composition is in the range of more than 7 and not more than 9.5. The pH may be in the range of 7.2 to 9.5, 7.3 to 9.5 or 7.4 to 9.5. The pH of the stabilizing composition may also be not more than 9.25, not more than 9 or not more than 8.75, such as not more than 8.5, not more than 8.3 or not more than 8. These pH values may be combined with the previously indicated pH ranges as upper limits, the resulting ranges also forming part of the present disclosure. In one embodiment, the pH of the stabilizing composition is in the range of 7.5 to 9.5 or not more than 7.5 or not more than 9.5. In one embodiment, the pH of the stabilizing composition is in the range of 7.2 to 8.5 or not more than 7.3 to 8.3 or not more than 7.5 to 8. The pH of the stabilizing composition may further be in the range of 7.7 to 9.5 or 8 to 9.25. According to a further embodiment, also shown in the examples, the pH of the stabilizing composition is in the basic range of 8 to 9.
[0072] According to one embodiment, the stabilizing composition is a liquid composition contacted with the urine sample in a volume ratio selected from 1:3 to 1:10, preferably 1:5 to 1:10. It is particularly advantageous that stabilization and pH adjustment of a large volume of urine can be achieved with a small volume of the stabilizing composition according to the invention. Preferably, the ratio of stabilizing composition to sample is in the range of 1:5 to 1:8, for example about 1:6. For example, 1-2 ml, for example 1.3 ml to 1.7 ml of the liquid stabilizing composition may be contacted with approximately 10 ml of urine.
[0073] As demonstrated by the examples, the stabilization composition with a higher pH value, preferably above 7, is more effective in preserving cell-free DNA, because the degradation of cell-free DNA is more effectively prevented compared to the stabilization composition with an acidic pH.This is very advantageous when the analysis of cell-free DNA contained in urine sample is intended.As can be seen from the examples, the higher pH of the stabilization composition, for example, especially the basic pH above 7, effectively prevents the degradation of cell-free DNA, even when the stabilized urine sample is stored for several days.
[0074] The stabilizing composition preferably includes a buffer for pH adjustment. The buffer may have its pK in the basic range. A suitable and preferred buffer is Tris, as demonstrated by the examples. Other buffers include, but are not limited to, MOPS, TES, HEPES, TAPSO, Tricine, Bicine, TAPS, borate buffers, CHES buffers or buffers based on sodium or potassium phosphate. Further buffers include carbonates. The pH of urine can vary from acidic to basic depending on the donor and also on the donor's condition. Thus, it is advantageous to include a sufficient concentration of buffer to achieve efficient pH adjustment and stabilization, despite possible variations in the pH of the collected urine sample to be stabilized. Suitable concentrations can be determined by those skilled in the art.
[0075] According to one embodiment, the final pH of the stabilized urine sample is in the range of 6 to 9.5, such as 6.3 to 9.5. The final pH of the stabilized urine sample may be 9 or less, such as 8.75 or less or 8.5 or less. A pH of the stabilized urine sample in the range of 6.5 to 9, such as 6.5 to 8.75 or 6.5 to 8.5, is particularly suitable. In an embodiment, the pH of the stabilized urine sample may be in the range of 6.7 to 9 or 7 to 9, such as 7.2 to 9 or 7.2 to 8.75. According to one embodiment, the final pH of the stabilized urine sample may be at least 7 or above 7, such as in the range of 7.5 to 8.5. Caspase inhibitors
[0076] According to one embodiment, the urine sample is further contacted with at least one caspase inhibitor.It is also within the scope of the present invention to use a combination of various caspase inhibitors.The use of a caspase inhibitor can improve the stabilization effect achieved.The caspase inhibitor may be included in the stabilization composition that is contacted with the urine sample for stabilization.Preferably, the stabilization composition according to the third aspect is used for this purpose.
[0077] Preferably, the caspase inhibitor is cell permeable. Members of the caspase gene family play important roles in apoptosis. The substrate selectivity or specificity of individual caspases has been exploited to develop peptides that compete well with caspase binding. By linking caspase-specific peptides to, for example, aldehyde, nitrile or ketone compounds, it is possible to generate reversible or irreversible inhibitors of caspase activation. For example, fluoromethylketone (FMK) derivatized peptides such as Z-VAD-FMK act as effective irreversible inhibitors without additional cytotoxic effects. Inhibitors synthesized with a benzyloxycarbonyl group (BOC) at the N-terminus and O-methyl side chain have shown enhanced cell permeability. More suitable caspase inhibitors are synthesized with a phenoxy group at the C-terminus. One example is Q-VD-OPh, a cell permeable, irreversible broad-spectrum caspase inhibitor that is even more effective in preventing apoptosis, and thus supporting stabilization, than the caspase inhibitor Z-VAD-FMK.
[0078] According to one embodiment, the caspase inhibitor is a pan-caspase inhibitor and thus a broad spectrum caspase inhibitor.
[0079] According to one embodiment, the caspase inhibitor is a caspase-specific peptide. Preferably, said caspase-specific peptide is modified. It may be modified by an aldehyde, nitrile or ketone compound. According to one embodiment, the caspase-specific peptide is modified at the carboxyl terminus, preferably with an O-phenoxy (OPh) group or a fluoromethylketone (FMK) group. According to one embodiment, the caspase inhibitor is selected from the group consisting of Q-VD-OPh and Z-VAD(OMe)-FMK. In a preferred embodiment, Q-VD-OPh, a broad-spectrum inhibitor against caspases, is used for stabilization. Q-VD-OPh is cell-permeable and inhibits cell death by apoptosis. Q-VD-OPh is not toxic to cells even at very high concentrations and contains a carboxy-terminal phenoxy group conjugated to the amino acids valine and aspartic acid. It is equally effective in preventing apoptosis mediated by the three major apoptotic pathways: caspase-9 and caspase-3, caspase-8 and caspase-10, and caspase-12 (Caserta et al, 2003). Examples of caspase inhibitors are also listed in Table 1 of WO2013 / 045457.
[0080] The stabilized urine sample, i.e. the mixture obtained after contacting the urine sample with the caspase inhibitor and the further additive, may contain the caspase inhibitor (or combination of caspase inhibitors) at a final concentration of at least 0.5 μM. Embodiments include concentrations of at least 1 μM, for example at least 1.5 μM, at least 2 μM or at least 2.5 μM. When the urine sample and the further additive are mixed, suitable final concentration ranges for the caspase inhibitor include, but are not limited to, 1 μM to 25 μM. Embodiments include 1.5 μM to 20 μM and 2 μM to 15 μM. Final concentration ranges of 2 μM to 12.5 μM, 2.5 μM to 10 μM and 3 μM to 7.5 μM are preferred. The above concentrations apply to the use of a single caspase inhibitor as well as to the use of a combination of caspase inhibitors. The aforementioned concentrations are particularly suitable when using pan-caspase inhibitors, in particular modified caspase-specific peptides such as Q-VD-OPh and / or Z-VAD(OMe)-FMK. Suitable concentration ranges for individual caspase inhibitors and / or other urine samples can be determined by one skilled in the art, for example by testing various concentrations of each caspase inhibitor in the test assays described in the Examples. Amide
[0081] According to one embodiment, the urine sample is further contacted with one or more primary, secondary or tertiary amides as further stabilizing agents. A combination of two or more primary, secondary or tertiary amides can also be used. The amide is preferably a carboxylic acid amide.
[0082] Suitable concentrations for various primary, secondary or tertiary amides can be determined by those skilled in the art, for example by testing various concentrations in the test assay described in the Examples. In general, when a urine sample is contacted with one or more primary, secondary or tertiary amides and further additives, the resulting mixture may contain said amide (or combination of amides) at a final concentration of at least 0.05%. For example, the final concentration may be at least 0.1%, at least 0.25%, at least 0.5% or at least 0.75%. Suitable concentration ranges include, but are not limited to, 0.1% to 10%, 0.25% to 7.5%, 0.3% to 5%, 0.4% to 3%, 0.5% to 2%, 0.6% to 1.8% or 0.75% to 1.5%. Concentrations or concentration ranges given as percentage values, as used herein, are given in particular as weight percentage per volume (w / v) for solid amides and as volume percentage per volume (v / v) for liquid amides.
[0083] According to one embodiment, said amide(s) is / are included in a stabilizing composition that is contacted with the urine sample for stabilization. Preferably, a stabilizing composition according to the third aspect is used for this.
[0084] According to one embodiment, the primary, secondary or tertiary amide is a compound according to formula 1 [ka] (wherein R1 is a hydrogen or alkyl residue, preferably a C1-C5 alkyl residue, a C1-C4 alkyl residue or a C1-C3 alkyl residue, more preferably a C1-C2 alkyl residue; R2 and R3 are the same or different and are selected from hydrogen and hydrocarbon residues, preferably alkyl residues having a carbon chain length of 1 to 20 atoms arranged in a linear or branched manner; and R4 is an oxygen, sulfur or selenium residue, preferably R4 is oxygen. It is.
[0085] Combinations of one or more compounds according to Formula 1 may further be used for urine stabilization.
[0086] In embodiments where R1 is an alkyl residue, chain lengths of 1 or 2 are preferred for R1.
[0087] R2 and / or R3 of the compound according to formula 1 are the same or different and are selected from hydrogen residues and hydrocarbon residues, preferably alkyl residues. According to one embodiment, R2 and R3 are both hydrogen. According to one embodiment, one of R2 and R3 is hydrogen and the other is a hydrocarbon residue. According to one embodiment, R2 and R3 are the same or different hydrocarbon residues. The hydrocarbon residues R2 and / or R3 may be selected independently from each other from the group including alkyl, including short chain alkyl and long chain alkyl, alkenyl, alkoxy, long chain alkoxy, cycloalkyl, aryl, haloalkyl, alkylsilyl, alkylsilyloxy, alkylene, alkenediyl, arylene, carboxylate and carbonyl. The chain length n of R2 and / or R3 may have the values 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20 in particular. According to one embodiment, R2 and R3 have a carbon chain length of 1 to 10, preferably 1 to 5, more preferably 1 to 2. According to one embodiment, R2 and / or R3 are alkyl residues, preferably C1 to C5 alkyl residues.
[0088] Preferably, the compound according to formula 1 is a carboxylic acid amide, where R4 is oxygen. It may be a primary, secondary or tertiary carboxylic acid amide.
[0089] According to one embodiment, the compound according to formula 1 is an N,N-dialkyl-carboxylic acid amide. The preferred R1, R2, R3 and R4 groups are described above. The use of each compound according to formula 1 can support the stabilization of intracellular nucleic acids in urine samples. Further stabilization of intracellular nucleic acids is advantageous, since it allows subsequent analysis of the intracellular nucleic acids contained in the stabilized cells. According to one embodiment, the compound according to formula 1 is selected from the group consisting of N,N-dimethylacetamide, N,N-diethylacetamide, N,N-dimethylformamide and N,N-diethylformamide. Also suitable as R4 are the respective thio analogues containing sulfur instead of oxygen. N,N-dimethylacetamide (DMAA), for example, achieves good stabilization results, but is a toxic agent. Preferably, at least one compound according to formula 1 is used in combination with a poly(oxyethylene) polymer for stabilizing urine samples, which is not a toxic agent according to the GHS classification.
[0090] According to one embodiment, the urine sample is further contacted with a compound according to formula 1, which is an N,N-dialkylpropanamide, such as N,N-dimethylpropanamide, for stabilization. As demonstrated in the examples, each combination is suitable for stabilizing cell-free DNA in urine.
[0091] According to one embodiment, the urine sample is further contacted with at least one compound according to formula 1, which is a primary or secondary carboxylic acid amide. As can be seen from WO2014 / 146781, primary and secondary carboxylic acid amides are capable of stabilizing extracellular nucleic acid populations over a wide concentration range. According to one embodiment, the primary carboxylic acid amide is selected from the group consisting of formamide, acetamide, propanamide and butanamide. According to one embodiment, the primary carboxylic acid is butanamide. The stabilizing effect of butanamide on extracellular nucleic acid populations is also described in detail in WO2014 / 146780 and WO2014 / 146782.
[0092] According to one embodiment, the urine sample is contacted with EDTA, poly(oxyethylene) polymer (preferably polyethylene glycol), a preservative for inhibiting bacterial growth, and butanamide and / or N,N-dialkylpropanamide for stabilization, said N,N-dialkylpropanamide being preferably N,N-dimethylpropanamide. The above suitable and preferred concentrations and concentration ranges for primary, secondary and tertiary amides in general also apply specifically to this embodiment. As shown by the examples, the use of a stabilization composition comprising butanamide and / or N,N-dialkylpropanamide at concentrations within these ranges provides an advantageous stabilization effect for urine samples. Extracellular (cell-free) DNA
[0093] As demonstrated in the examples, the stabilization method according to the present invention efficiently stabilizes extracellular (cell-free) DNA, which is particularly useful for diagnostic purposes. Therefore, it is important to efficiently inhibit the degradation of cell-free DNA contained in urine samples.
[0094] The stabilization technique according to the invention is particularly advantageous in this respect, since it substantially preserves the extracellular DNA contained in the urine sample, e.g. inhibits degradation of the extracellular DNA contained therein (preferably by at least 50%, at least 60% or at least 70% over the stabilization period compared to time 0 immediately after stabilization).
[0095] A further problem after collecting urine samples may be the contamination and dilution of cell-free DNA contained in collected urine samples by intracellular nucleic acids, especially fragmented genomic DNA originating from damaged or dying cells contained in the urine sample. According to one embodiment, the stabilization method reduces the increase in DNA caused by the release of genomic DNA from cells contained in the urine sample during the stabilization period compared to unstabilized samples. The release of DNA can be determined, for example, by quantifying ribosomal 18S DNA, as described herein in the Examples section. As shown in the Examples, the stabilization achievable by the teachings of the present invention can reduce this release of DNA over the stabilization period. However, as shown above, the degradation of cell-free DNA during storage is a more important issue for urine samples, since the priority is to prevent the degradation and therefore the loss of cell-free DNA present at the time of collection during storage. As shown by the Examples, effective stabilization of cell-free DNA can be achieved by the methods of the present invention for at least 3 days, and even up to 6 days and longer. However, the sample may be processed even earlier if desired. It is not necessary to utilize the full achievable stabilization period.
[0096] Furthermore, the examples demonstrate that the cells are stabilized and suitable for cytological analysis.Furthermore, genomic DNA can be isolated from the contained cells.
[0097] Furthermore, because stabilization does not result in cross-linking of the samples, nucleic acids can be efficiently isolated from each stabilized sample using a variety of standard methods, greatly simplifying and improving the standardization of molecular analyses that rely on the analysis of nucleic acids obtained from stabilized urine samples. Further Additives
[0098] Additional additives can also be used to further support the stabilization of urine sample and the preservation of extracellular nucleic acid population, respectively.Examples of each additive include, but are not limited to, nuclease inhibitors, particularly RNase and DNase inhibitor compounds.As shown in the examples, furthermore, diethylene glycol methyl ether acetate (DEGMEA) can be included.
[0099] When selecting each additional additive to support stabilization, care should be taken not to impair and / or hinder the stabilizing effect of the core stabilizing agent. Thus, additives such as, for example, chaotropic agents should be used at concentrations that cause or support the lysis and / or degradation of nucleated cells contained in the stabilized urine sample and / or support the degradation of cell-free DNA contained in the cell-free fraction in the urine sample. Thus, preferably, the stabilization method described herein does not involve the use of additional additives that (i) induce or promote the lysis of nucleated cells, (ii) induce or promote the lysis of cells in general, and / or (iii) cause the degradation of nucleic acids contained in the cell-free fraction of the urine sample, for example, in particular cell-free DNA. Although the stabilization method described herein is not based on cell lysis, it is also possible to preserve cells, so that the cells can be separated from the urine sample after the stabilization period, thereby making it possible to obtain a cell-free or cell-depleted urine fraction containing extracellular DNA and a cell sample. The extracellular DNA population preferably corresponds substantially to, or at least closely resembles, the extracellular DNA population present at the time of urine collection and stabilization. Furthermore, intracellular nucleic acid such as genomic DNA can be isolated from the separated cells and is available for analysis.Therefore, each stabilized sample allows separate analysis of extracellular and intracellular nucleic acid such as cell-free DNA and genomic DNA from the same stabilized sample, if desired.Furthermore, the cells themselves can be analyzed by cytological methods, as demonstrated in the examples. Further embodiments
[0100] Further advantageous embodiments of the method according to the first aspect are described below.
[0101] According to one embodiment, there is provided a method for stabilizing a urine sample, the method comprising the steps of: - EDTA as a chelating agent, at least one polyethylene glycol, preferably at least one high molecular weight polyethylene glycol having a molecular weight of at least 3000 and / or at least one low molecular weight polyethylene glycol having a molecular weight of 1000 or less, - a preservative to inhibit bacterial growth, - buffering agents, - at least one caspase inhibitor, and - optionally at least one primary, secondary or tertiary amide A method is provided comprising contacting the
[0102] 1. A method for stabilizing a urine sample, comprising: EDTA as a chelating agent, the final concentration of EDTA in the stabilized urine sample being in the range of 7 mg / ml to 40 mg / ml, preferably 10 mg / ml to 30 mg / ml, for example 15 mg / ml to 30 mg / ml, at least one polyethylene glycol, preferably at least one high molecular weight polyethylene glycol having a molecular weight of at least 6000 and / or at least one low molecular weight polyethylene glycol having a molecular weight of 1000 or less, - a preservative to inhibit bacterial growth, - buffering agents, - at least one caspase inhibitor, and - optionally at least one primary, secondary or tertiary amide Also provided is a method comprising contacting the
[0103] 1. A method for stabilizing a urine sample, comprising: EDTA at a concentration of at least 100 mM up to its solubility limit, preferably in the range of 150 mM to 500 mM, so that in the stabilized urine sample the final concentration of EDTA is in the range of 7 mg / ml to 40 mg / ml, preferably 10 mg / ml to 30 mg / ml, for example 15 mg / ml to 30 mg / ml, at least one polyethylene glycol, preferably at least one high molecular weight polyethylene glycol having a molecular weight of at least 6000 and optionally at least one low molecular weight polyethylene glycol having a molecular weight of 1000 or less, - a preservative to inhibit bacterial growth, - Buffering agents, as well as - Optionally, at least one caspase inhibitor with a liquid stabilizing composition comprising the pH of the stabilized composition is in the range of greater than 7 to 9.5, e.g., 7.2 to 9, 7.2 to 8.75, or 7.3 to 8.5; Also provided is a method in which the stabilizing composition is contacted with the urine sample for stabilization in a volume ratio selected from 1:3 to 1:10, preferably 1:5 to 1:8. The final pH in the stabilized urine sample may be in the range of 6 to 9.5, for example 6.3 to 9.5 or 6.5 to 9. As shown by the examples, the use of a stabilizing composition according thereto makes it possible, inter alia, to bring about a final pH of the stabilized urine sample in the range of 6.5 to 8.75, for example 6.5 to 8.5. A good stabilizing effect is achieved. The final pH of the stabilized urine sample may even be greater than 7, as shown by the examples. Preferred embodiments and concentrations of polyethylene glycol, preservatives and buffers are disclosed above. The stabilizing composition may comprise at least one primary, secondary or tertiary amide as disclosed herein.
[0104] The chelating agent, the poly(oxyethylene) polymer and optionally a preservative for inhibiting bacterial growth (core stabilizing agent) as well as further stabilizing agents and / or additives that may be used optionally, such as in particular a buffer and a caspase inhibitor, may be present in the device for receiving the urine sample, preferably in the container. The core stabilizing agent and optionally one or more compounds further used for stabilization may be present in a stabilizing composition, such as a stabilizing composition according to the third aspect, present in each device, or may be present as separate entities. Moreover, they may be added to each receiving device before receiving the urine sample or may be added to the receiving device after receiving the urine sample therein. It is also within the scope of the present invention to add the stabilizing agent and optionally further additives used separately to the urine sample for stabilization. However, with regard to ease of handling, it is preferred that the core stabilizing agent and any further stabilizing agents and / or additives used are provided in each receiving device, for example in the form of a single composition. However, they may be present as separate components or compositions in the receiving device. In an advantageous embodiment, the core stabilizing agent, at least one caspase inhibitor and optionally further additives are present in the receiving device before adding to the urine sample. This ensures that the urine sample is rapidly stabilized when it comes into contact with the stabilizing agent used according to the teachings of the present invention. The stabilizing agent is present in the container in an amount effective to stabilize the amount of urine sample collected, and is contained in the receiving device, respectively. Suitable and preferred embodiments for each receiving device are also described below in conjunction with the fifth embodiment, the disclosure of which is incorporated herein by reference. As described herein, urine may be first collected in a standard urine collection device and then transferred to the receiving device of the present invention for stabilization of the urine.
[0105] Preferably, the urine sample is contacted with the core stabilizing agent and, if necessary, further additives immediately after collection of the urine sample.In an embodiment, contacting occurs during urine collection from the donor, for example by providing the stabilizing agent in a collection container such as a urine cup.As mentioned above, preferably, the agent used for stabilization is provided in the form of a stabilizing composition, such as the stabilizing composition according to the third aspect.Preferably, said stabilizing composition is provided in liquid form.It may, for example, be prefilled in the sample receiving device, so that the urine sample is rapidly stabilized when it enters the device.
[0106] The use of the stabilization method according to the invention has the advantage that, substantially independent of the composition of the urine sample and the number of cells contained therein, the extracellular DNA and the intracellular nucleic acids, such as the exfoliated cells and the genomic DNA contained in said sample, can be substantially preserved and respectively stabilized, thereby allowing the standardization of the subsequent isolation and / or analysis of the contained cell-free DNA and other stabilized components. In an embodiment, the stabilization method achieves the stabilization of the cells contained in the urine sample, so that the cells can be utilized for the isolation of intracellular nucleic acids, such as the genomic DNA, and / or for cytological analysis.
[0107] According to one embodiment, the extracellular RNA is stabilized in addition to the extracellular DNA.
[0108] The term "extracellular nucleic acid(s)" as used herein refers specifically to nucleic acids that are not contained within a cell. Each extracellular nucleic acid is often referred to as cell-free nucleic acid. These terms are used synonymously herein. Thus, extracellular nucleic acid is usually present outside one cell or outside multiple cells in a sample. The term "extracellular nucleic acid" refers, for example, to extracellular DNA and extracellular RNA. Cell-free DNA in urine is of particular interest. Examples of typical extracellular nucleic acids found in the cell-free fraction of urine (respectively, a portion of urine) include, but are not limited to, mammalian extracellular nucleic acids, such as extracellular tumor-associated or tumor-derived DNA and / or RNA, other extracellular disease-associated DNA and / or RNA, epigenetically modified DNA, fetal DNA, and non-mammalian extracellular nucleic acids, such as viral nucleic acids, such as pathogen nucleic acids released into the extracellular nucleic acid population from prokaryotes (e.g., bacteria), viruses, eukaryotic parasites, or fungi. The extracellular nucleic acid population typically comprises a certain amount of intracellular nucleic acid released from damaged or dying cells prior to or during collection of the urine sample.
[0109] According to one embodiment, the term extracellular nucleic acid or extracellular DNA refers in particular to mammalian extracellular nucleic acid, mammalian extracellular DNA, respectively. Examples include, but are not limited to, disease-related or disease-derived extracellular nucleic acid, such as tumor-related or tumor-derived extracellular nucleic acid, inflammation or injury, especially trauma-released extracellular nucleic acid, other disease-related and / or released due to other diseases, or fetal-derived extracellular nucleic acid.
[0110] The term "extracellular nucleic acid population" or "extracellular DNA population" as used herein refers to a collection of various extracellular nucleic acids, such as DNA, contained in a urine sample. The extracellular DNA population is of particular interest. A urine sample is usually characterized and therefore contains a unique extracellular nucleic acid population. Thus, the type, variety, ratio and / or amount of one or more extracellular nucleic acids contained in the extracellular nucleic acid population of a urine sample can be an important sample feature. As discussed above, it is therefore advantageous to stabilize and thus substantially preserve the extracellular DNA population in the state in which the urine sample is collected, since the type, composition and / or amount of one or more extracellular nucleic acids contained in the extracellular nucleic acid population of the sample can provide useful medical, prognostic or diagnostic information. Therefore, it is advantageous if the profile of the extracellular nucleic acid population, e.g., cell-free DNA, is efficiently stabilized over the intended stabilization period. The stabilization techniques described herein reduce the degradation of the contained cell-free DNA. Thus, substantial preservation of the extracellular DNA population is achieved. In embodiments, the stabilization further reduces the contamination and therefore the dilution of extracellular nucleic acids by intracellular nucleic acids, particularly genomic DNA, after urine sample collection and stabilization. In embodiments, the release of genomic DNA from cells contained in the sample into the cell-free portion of the urine sample is reduced by the stabilization.
[0111] The stabilization method described herein reduces the risk that extracellular DNA is rapidly degraded in collected urine samples. The degradation of cell-free DNA in urine samples is reduced by stabilization. Therefore, it is particularly advantageous to directly transfer collected urine samples into a receiving device that already contains a stabilization composition, thereby stabilizing the urine sample immediately after collection. This reduces the alteration of extracellular DNA population due to ex vivo handling. If urine is first collected and handled before being stabilized, the risk that extracellular DNA is rapidly degraded in the intermediate period increases.
[0112] As described above and demonstrated by examples, the method of the present invention allows stabilization of urine samples without refrigeration or freezing for long periods of time.Therefore, the sample can be kept at room temperature or at elevated temperatures, for example up to 30°C or even up to 40°C. According to one embodiment, the stabilization effect is achieved for at least 3 days, preferably at least 4 days, more preferably at least 6 days or up to 9 days.
[0113] Generally, the stabilizing effect decreases over time, which may vary depending on the source, e.g., which donor the urine sample comes from, but generally, it is still sufficient to preserve the urine sample. Thus, the urine sample stabilized according to the method of the present invention was still suitable for the isolation and analysis of the extracellular DNA contained therein, even after extended storage at room temperature. Thus, even longer storage / transportation can be considered. However, longer periods are not necessary, since the usual storage and, e.g., transport time to the laboratory where nucleic acid isolation and further analysis, if necessary, are usually performed, usually do not exceed 3, 6 or 7 days. As shown in the examples, substantial stabilizing effect is achieved over this period. The long-term stabilization and stabilization efficiency achievable by the method according to the present invention provide an important safety factor.
[0114] The method according to the invention, and also the stabilizing composition described below, allows the stabilization of a large volume of urine sample even with a small volume / amount of stabilizer added, because the described combination of core stabilizer and stabilizer is highly active, especially in combination. This is an important advantage, since the volume of the urine sample imposes a significant limitation on the subsequent nucleic acid isolation procedure when an automated process is intended to be used to isolate extracellular nucleic acids, such as cell-free DNA, contained in the sample. Furthermore, it must be considered that extracellular nucleic acids are usually only present in small amounts in urine samples. Thus, processing a large volume of urine sample has the advantage that more extracellular nucleic acids can be isolated from the sample and thus available for subsequent analysis.
[0115] According to one embodiment, the urine volume stabilized using the method of the first aspect is selected from 1 ml to 150 ml, 2 ml to 100 ml, 2.5 ml to 75 ml or 3 ml to 50 ml. For many analytical purposes, stabilization of a smaller volume of urine is sufficient, and the use of a reduced pressure receiving device, such as a tube, containing a stabilizing agent to advantageously perform the stabilization. For example, urine can be transferred from the original urine collection container (which can accept a larger volume, for example, up to 200 ml), into a receiving device, such as a reduced pressure tube, containing a stabilizing agent, preferably a stabilizing composition according to the third aspect. According to one embodiment, the receiving device containing the stabilizing agent can, for example, accept 2 ml to 50 ml, 3 ml to 30 ml, 4 ml to 25 ml, or 5 ml to 20 ml, for example up to 10 ml of urine.
[0116] The method may have one or more of the following features: i) stabilization does not involve the use of an additive at a concentration at which the additive induces or promotes lysis of nucleated cells; ii) the stabilization does not involve the use of cross-linking agents that induce protein-nucleic acid and / or protein-protein cross-links, such as formaldehyde, formalin, paraformaldehyde or formaldehyde-releasing agents; and / or iii) The stabilized sample is held for at least 1 day or at least 2 days before processing the stabilized sample.
[0117] The stabilization method disclosed herein offers considerable advantages over current stabilization methods used to stabilize extracellular nucleic acid populations in urine samples, which are based on the use of cross-linking reagents, such as formaldehyde, formalin, formaldehyde-releasing agents, etc. (see, e.g., Streck). Cross-linking reagents result in inter- or intra-molecular covalent bonds between nucleic acid molecules or between nucleic acids and proteins. Cross-linking effects can significantly impair the subsequent isolation of nucleic acids from such stabilized samples, and usually require specifically adapted nucleic acid isolation procedures to allow isolation from such samples. For example, the concentration of cell-free DNA or target sequences in urine samples may already be relatively low, so any measures that further reduce the yield of such nucleic acids should be avoided. This may be particularly important when detecting and analyzing very rare nucleic acid molecules, for example, derived from malignant tumors or developing fetuses. As shown by the examples, the urine stabilization method of the present invention does not require a cross-linking agent for stabilization. Thus, according to one embodiment, the stabilization method according to the present invention does not involve the use of cross-linking agents that induce protein-nucleic acid and / or protein-protein cross-links. In particular, the stabilization does not involve the use of formaldehyde, formalin, paraformaldehyde or formaldehyde-releasing agents.
[0118] According to a preferred embodiment, the urine sample initially collected in a different device is then exclusively contacted with a stabilizing composition comprising a stabilizing agent, such as the stabilizing composition according to the third aspect, for stabilization, whereby stabilizing conditions are established by the stabilizing composition.
[0119] After the stabilization period, the method may include one or more of the following: extracellular nucleic acid, preferably cell-free DNA, is isolated from the stabilized urine sample and, if necessary, further analyzed and / or detected. Cells contained in the stabilized urine sample may be removed. According to one embodiment, cells contained in the stabilized urine sample are removed and cell-free DNA is isolated from the cell-free or cell-depleted portion of the stabilized sample. According to one embodiment, the removed cells are discarded. However, the method of the invention may include a step of removing cells from the stabilized urine sample and a step of isolating nucleic acid, preferably genomic DNA, from the cells removed from the stabilized urine sample. Furthermore, the method may include a step of removing cells from the stabilized urine sample and a step of analyzing the removed cells using cytological methods.
[0120] According to one embodiment, (i) the stabilized urine sample, (ii) the cell-depleted stabilized urine sample and / or (iii) the cells removed from the stabilized urine sample are stored.
[0121] Thus, the stabilized urine sample can be analyzed in a nucleic acid analysis and / or detection method and / or further processed, and the method of the invention allows for the analysis of stabilized cell-free DNA, cells and / or intracellular nucleic acids by multiple analytical options. Details regarding the isolation and analysis of nucleic acids are also described below in conjunction with the second aspect of the invention, the disclosure of which is referenced. B. Methods for Processing Urine Samples
[0122] According to a second aspect, there is provided a method for processing a urine sample, comprising the steps of: a) stabilising a urine sample according to the method defined in the first aspect, and b) isolating cells from the stabilized urine sample, thereby providing (i) a cell sample and (ii) a cell-depleted supernatant. A method is provided, comprising:
[0123] Details of this method are also defined in claims 16 and 17. The individual steps are described in more detail below. Step a)
[0124] In step a), the urine sample is stabilized according to the method described in the first aspect of the present invention as detailed above, in particular using the method according to any one of claims 1 to 15. As discussed above, the stabilization according to the present invention has the effect that cell-free DNA is substantially preserved from degradation over the stabilization period. Furthermore, intracellular nucleic acids such as cellular and genomic DNA are preserved as demonstrated in the examples.
[0125] The stabilization according to the present invention does not require and preferably does not involve the use of cross-linking agents.This is an important advantage over the prior art methods that involve the use of cross-linking agents such as formaldehyde, formalin or formaldehyde-releasing agents, because these agents often reduce the recoverable amount of extracellular nucleic acid by cross-linking when using standard nucleic acid isolation techniques.Furthermore, as mentioned above, the stabilization described herein allows the sample to be stored and / or handled, for example, transported (even at room temperature), for an extended period of time before separating the cells contained in the urine sample in step b).
[0126] Regarding the details of the stabilization carried out in step a), reference is made to the above disclosures which also apply here. Preferably, the urine sample is contacted with a stabilizing composition according to the third aspect for stabilization. Step b)
[0127] In step b), cells are separated from the stabilized urine sample, thereby obtaining (i) a cell sample and (ii) a cell-depleted supernatant.
[0128] The cells may be separated and thus removed, for example, by centrifugation, preferably high-speed centrifugation, or by using means other than centrifugation, such as, for example, filtration, sedimentation or binding to a surface, for example, binding to particles (optionally, magnetic particles) if the centrifugation step is to be avoided. Each cell separation method is well known in the prior art and therefore does not need to be described in detail. Each cell removal step can also be easily included in an automated sample preparation protocol. Preferably, essentially all cells are removed to provide an essentially cell-free or cell-free supernatant.
[0129] The removed cells may be processed, if desired, as described below. The cells may, for example, be stored, analyzed (e.g., using cytological methods), and / or biomolecules, such as, for example, nucleic acids or proteins, may be isolated from the removed cells.
[0130] According to one embodiment, step b) is performed within minutes or hours after stabilizing the urine sample. According to one embodiment, step b) is performed at least 1 to 3 days or 2 to 9 days after the urine sample is collected and stabilized, respectively, according to the teachings of the present invention. Further steps
[0131] Furthermore, it is within the scope of the invention to include additional steps for post-processing the stabilized urine sample, the resulting cell sample and / or the cell-depleted supernatant.
[0132] According to one embodiment, the method further comprises the step of purifying extracellular nucleic acids, such as preferably extracellular DNA, from the cell-depleted supernatant.
[0133] According to one embodiment, the method further comprises purifying intracellular nucleic acid, preferably genomic DNA, from the obtained cell sample.As demonstrated in the examples, the method allows processing and analysis of the extracellular and intracellular nucleic acids, such as extracellular and genomic DNA, contained in the stabilized urine sample.As shown by the examples, the extracellular DNA fraction can be analyzed separately from genomic DNA.
[0134] According to one embodiment, nucleic acid isolation is performed within 1 to 3 days or 2 to 9 days after the urine sample has been collected and stabilized according to the method according to the invention.
[0135] Any suitable nucleic acid isolation method can be used to isolate nucleic acid, and suitable methods are well known and commercially available.Examples of each purification method include, but are not limited to, extraction, solid phase extraction, silica-based purification method, magnetic particle-based purification, phenol-chloroform extraction, chromatography, anion exchange chromatography (using anion exchange surface), electrophoresis, filtration, precipitation and combinations thereof.It is also within the scope of the present invention to specifically isolate specific target extracellular nucleic acid, for example, by using a suitable probe linked to a solid support that allows sequence-specific binding.Any other nucleic acid isolation technique known to those skilled in the art can be used.
[0136] According to one embodiment, nucleic acids are isolated from cell-depleted supernatant using chaotropic agents and / or alcohol. Preferably, nucleic acids are isolated by binding them to a solid phase, preferably a solid phase comprising silica and having an anion exchange functional group. Each method is well known in the prior art and therefore does not require any detailed description. Methods and kits suitable for isolating extracellular nucleic acids are also commercially available, such as QIAamp® Circulating Nucleic Acid Kit (QIAGEN), Chemagic Circulating NA Kit (Chemagen), NucleoSpin Plasma XS Kit (Macherey-Nagel), Plasma / Serum Circulating DNA Purification Kit (Norgen Biotek), Plasma / Serum Circulating RNA Purification Kit (Norgen Biotek), High Pure Viral Nucleic Acid Large Volume Kit (Roche) and other commercially available kits suitable for extracting and purifying extracellular nucleic acids.
[0137] According to one embodiment, nucleic acids are isolated by binding them to a solid phase that contains anion exchange groups. Suitable anion exchange groups are provided, for example, by amine groups. Binding preferably occurs at a pH lower than 7. Such anion exchange-based nucleic acid isolation method is known to those skilled in the art. According to one embodiment, nucleic acid is extracellular nucleic acid. Suitable anion exchange-based methods are described, for example, in WO2013 / 045432, which is incorporated herein by reference.
[0138] According to one embodiment, total nucleic acid is isolated from the cell-depleted supernatant. It is also within the scope of the present invention to isolate at least predominantly specific target nucleic acid. The target nucleic acid may be, for example, a specific type of extracellular nucleic acid, for example, DNA or RNA (including miRNA, snRNA, lincRNA), preferably DNA. For example, the target extracellular nucleic acid may be DNA and the non-target extracellular nucleic acid may be RNA. Target-specific nucleic acid isolation methods specifically aimed at isolating DNA or RNA are also well known in the prior art and therefore do not require any detailed explanation here. According to one embodiment, the non-target nucleic acid is destroyed by adding a suitable enzyme that specifically destroys the non-target nucleic acid, for example, RNase if the target nucleic acid is DNA or DNase if the target nucleic acid is RNA. The enzyme can be added to the lysis solution or binding mixture or can be added after the extracellular nucleic acid is bound to the solid phase. Suitable embodiments for carrying out each non-target nucleic acid digestion step are known in the prior art and do not require any further explanation here. According to one embodiment, which can be carried out when DNA and RNA are bound to the solid support, selective elution conditions may be applied preferentially for the target nucleic acid, thus selectively recovering the target nucleic acid from the solid support. According to one embodiment, an isolation method is used in which the target nucleic acid, e.g. DNA, selectively binds to the solid phase under conditions in which non-target nucleic acid, e.g. RNA, does not bind. Suitable binding conditions are well known in the prior art and are described, for example, in WO95 / 21849. Methods for selectively removing non-target nucleic acid from the target nucleic acid are described, for example, in EP0880537 and WO95 / 21849, which are incorporated herein by reference. If desired, said non-target nucleic acid may also be further used, e.g., further processed, e.g., eluted from the solid phase. However, it may be discarded. For example, it is also within the scope of the present invention to use nucleases to digest the remainder after isolation of the non-target or target nucleic acid. The term target nucleic acid may refer to a particular type of nucleic acid, e.g., a particular extracellular nucleic acid known to be a particular disease marker.As discussed above, isolation of extracellular nucleic acids may involve specific isolation of each target nucleic acid, for example by using appropriate capture probes that support selective isolation of the target nucleic acids.
[0139] The term target nucleic acid may refer to a nucleic acid having a particular length. Size-selective nucleic acid, particularly DNA, isolation methods are known in the art. The classical method for isolating target-sized DNA involves separation of DNA in a gel, cutting out the desired gel band, and then isolating the target-sized DNA from the gel fragment. Another widely used technique is size-selective precipitation using polyethylene glycol-based buffers (Lis and Schleif Nucleic Acids Res. 1975 Mar;2(3):383-9) or binding / precipitation on carboxyl-functionalized beads (DeAngelis et al, Nuc. Acid. Res. 1995, Vol 23(22), 4742-3; US 5,898,071 and US 5,705,628, marketed by Beckman-Coulter (AmPure XP; SPRIselect) and US 6,534,262). In addition, size-selective isolation methods based on the use of solid supports containing anion exchange groups and varying pH values are known. Size-selective isolation provides further opportunities to reduce the amount of intracellular nucleic acids in the isolated extracellular nucleic acids. For example, if the target extracellular nucleic acid of interest is DNA, removal of genomic DNA during nucleic acid isolation could also complement or even replace another high G-force centrifugation to remove residual cells before starting nucleic acid extraction. The genomic DNA released from the residual cells is prevented from being degraded to a large extent due to stabilization according to the present invention, especially when a caspase inhibitor is further used, and therefore the unfragmented or less fragmented genomic DNA can be depleted by using a size-selective nucleic acid isolation protocol. This option is particularly advantageous because many clinical laboratories do not have centrifuges capable of performing such high G-force centrifugation or other means to remove particularly trace amounts of residual cells. Furthermore, a size-selective nucleic acid isolation protocol according to this can also deplete intracellular DNA, such as genomic DNA, during the nucleic acid isolation step, which would have been released during stabilization based on its larger size.This allows for the subsequent purification of stabilized (shorter) extracellular DNA that is less contaminated by genomic DNA.
[0140] According to one embodiment, the nucleic acids isolated from (i) the cell sample and / or (ii) the cell-free supernatant can then be analyzed and / or further processed, for example, using a suitable assay and / or analysis method. For example, they can be identified, modified, contacted with at least one enzyme, amplified, reverse transcribed, cloned, sequenced, contacted with a probe, detected (their presence or absence) and / or quantified. Each method is well known in the prior art and is usually applied in the medical, diagnostic and / or prognostic fields to analyze extracellular nucleic acids, such as cell-free DNA. Thus, the extracellular nucleic acid of interest can be isolated from the cell-free supernatant as a part of the total nucleic acid, for example total DNA and / or total RNA, if necessary, and analyzed to identify the presence, absence or severity of a disease state, including, for example, but not limited to, a number of neoplastic diseases, in particular pre-malignant and malignant tumors, such as various forms of tumors or cancer. For example, the isolated extracellular nucleic acid can be analyzed to detect diagnostic and / or prognostic markers (e.g., fetal- or tumor-derived extracellular nucleic acid) in many applications including, but not limited to, non-invasive prenatal genetic testing, disease screening, pathogen screening, oncology, cancer screening, early cancer screening, cancer treatment monitoring, genetic testing (genotyping), infectious disease testing, injury diagnosis, trauma diagnosis, transplantation medicine, or many other disease screening, respectively, and thus the isolated extracellular nucleic acid is of diagnostic and / or prognostic relevance. According to one embodiment, the isolated extracellular nucleic acid, such as cell-free DNA, is analyzed to identify and / or characterize a disease.
[0141] Analysis / further processing of the isolated nucleic acids may include, but is not limited to, amplification techniques, polymerase chain reaction (PCR), isothermal amplification, reverse transcription polymerase chain reaction (RT-PCR), quantitative real-time polymerase chain reaction (Q-PCR), digital PCR, gel electrophoresis, capillary electrophoresis, mass spectrometry, fluorescence detection, ultraviolet spectroscopy, hybridization assays, DNA or RNA sequencing, next generation sequencing, restriction analysis, reverse transcription, nucleic acid sequence-based amplification (NASBA), allele-specific polymerase chain reaction, polymerase cycling assembly (PCA), asymmetric polymerase chain reaction (ASCR), and the like. The nucleic acid analysis / processing method may be carried out using any nucleic acid analysis / processing method, including PCR (multiplexing reaction), linear-threshold exponential polymerase chain reaction (LATE-PCR), helicase-dependent amplification (HDA), hot-start polymerase chain reaction, intersequence-specific polymerase chain reaction (ISSR), inverse polymerase chain reaction, ligation-mediated polymerase chain reaction, methylation-specific polymerase chain reaction (MSP), multiplex polymerase chain reaction, nested polymerase chain reaction, solid-phase polymerase chain reaction, or any combination thereof. Each of these techniques is well known to those of skill in the art and therefore does not require further description herein.
[0142] According to one embodiment, the cells contained in the separated cell sample are analyzed. According to one embodiment, the cells are analyzed by cytological methods. Methods include, but are not limited to, centrifugation or smearing on a slide followed by histochemical or cytochemical staining, such as H&E, Periodic Acid Schiff (PAS), Resorcin-Fuchsin (RF; elastin stain), Sirius Red (SR; collagen stain), Gomori (GOM; reticulin stain) and Papanicolaou staining procedures. In addition, advanced staining methods, such as immunocytological staining or in situ hybridization (ISH), such as FISH (fluorescent), SISH (silver), CISH (chromogen), may be used. Furthermore, the cells can be resuspended and sorted by fluorescence-activated cell sorting (FACS) followed by molecular analysis. According to one embodiment, the method includes a step of preparing exfoliated cells from the obtained cell sample for cytological analysis. As demonstrated in the examples, the stabilization according to the present invention allows for subsequent cytological analysis of the stabilized cells. C. Stabilizing composition
[0143] According to a third aspect, there is provided a composition for stabilizing a urine sample, comprising: a chelating agent, preferably EDTA, at least one poly(oxyethylene) polymer, preferably polyethylene glycol, and optionally - A preservative to inhibit bacterial growth A composition is provided comprising:
[0144] Details of the stabilizing composition are also defined in claims 18 to 24.
[0145] The advantages and suitable and preferred embodiments of these core stabilizing compounds, as well as further stabilizing agents that may optionally be included in the stabilizing composition, such as caspase inhibitors, buffers and / or at least one primary, secondary or tertiary amide, have been discussed above in connection with the stabilization method according to the first aspect, and reference is made to the above disclosure which also applies here.
[0146] The suitable and preferred concentrations of each agent that can be used for stabilization in the stabilization mixture that includes the stabilization composition and the urine sample are described above and are applicable here.Those skilled in the art can select the appropriate concentration of said agent in the stabilization composition to achieve said concentration in the mixture that includes the urine sample when the intended amount of the stabilization composition is mixed with the intended amount of the urine sample that is stabilized according to the teachings of the present disclosure.Regarding the stabilization composition, reference is made to the above disclosure that is also applicable here.
[0147] According to one embodiment, the stabilizing composition is liquid. The components of the stabilizing composition may each be contained and dissolved in a solvent, such as water, a buffer, such as a biological buffer, such as TRIS, MOPS, PBS, etc. Suitable buffers are listed above. Furthermore, the components may be dissolved in a polar aprotic solvent, such as dimethyl sulfoxide (DMSO), or the stabilizing composition may include a polar aprotic solvent, such as dimethyl sulfoxide (DMSO). For example, 0.5 ml to 2.5 ml, 0.5 ml to 2 ml, preferably 1 ml to 2 ml, for example 1.3 ml to 1.7 ml of liquid stabilizing composition can be used. Such a stabilizing composition, particularly comprising the stabilizing agent in the concentration shown below, can be used to stabilize, for example, 10 ml of urine. pH
[0148] According to one embodiment, the stabilized composition has a pH in the range of 4.5 to 9.5. Preferably, the pH of the stabilized composition is in the range of more than 7 and not more than 9.5. The pH may be in the range of 7.2 to 9.5, 7.3 to 9.5 or 7.4 to 9.5. The pH of the stabilized composition may also be not more than 9.25, not more than 9 or not more than 8.75, such as not more than 8.5, not more than 8.3 or not more than 8. These pH values may be combined with the previously indicated pH ranges as upper limits, and the resulting ranges also form part of the present disclosure. In one embodiment, the pH of the stabilized composition is in the range of 7.5 to 9.5 or not more than 7.5 or not more than 9.5. In one embodiment, the pH of the stabilized composition is in the range of 7.2 to 8.5 or not more than 7.3 or not more than 8.3 or not more than 7.5 to 8. The pH of the stabilized composition may further be in the range of 7.7 to 9.5 or 8 to 9.25. According to a further embodiment, also shown in the examples, the pH of the stabilizing composition is in the basic range of 8 to 9.
[0149] The stabilization composition preferably comprises a suitable buffering agent that allows maintaining the pH within the desired range when the urine sample is added. Suitable and preferred embodiments of the buffering agent and its pH range in the stabilized urine sample are described above in conjunction with the method according to the first aspect to which reference is made. As discussed, the selected pH can have a significant effect on the stabilization result. A chelating agent, preferably EDTA
[0150] The chelating agent, preferably EDTA, is described in detail above, the disclosure of which is incorporated herein by reference. It may be included in the stabilizing composition in a concentration up to its solubility limit.
[0151] According to one embodiment, the liquid composition is provided as a stabilized composition comprising a chelating agent, preferably EDTA, such as K2EDTA, at a final concentration of at least 15 mM, such as at least 25 mM, at least 50 mM, at least 75 mM or at least 100 mM. It is advantageous to have a high concentration of the chelating agent in the stabilized composition. According to one embodiment, the stabilized composition comprises a chelating agent, preferably EDTA, at a concentration of 100 mM to the solubility limit or 150 mM to the solubility limit. Suitable final concentration ranges include 100 mM to 500 mM, 125 mM to 450 mM and 150 mM to 400 mM. Also, higher concentrations in the stabilized composition may be used, in the range of 175 mM to 400 mM, 200 mM to 400 mM or 250 mM to 350 mM. These concentrations are particularly suitable for EDTA. Poly(oxyethylene) polymers, preferably polyethylene glycol
[0152] The stabilizing composition comprises a poly(oxyethylene) polymer, preferably polyethylene glycol. Preferred embodiments are disclosed in conjunction with the first aspect, the disclosure of which is incorporated by reference.
[0153] According to one embodiment, the high molecular weight poly(oxyethylene) polymer is included in the stabilization composition. Details are described above in conjunction with the stabilization method according to the first aspect, and reference is made to the respective disclosures that apply here. The high molecular weight poly(oxyethylene) polymer is preferably a polyethylene glycol, such as unsubstituted polyethylene glycol. In an embodiment, the molecular weight is in a range selected from 1500 to 40000, for example 2000 to 35000, 2500 to 30000, 3000 to 25000 or 3500 to 20000. The range of 4000 to 20000, for example 5000 to 15000, is preferred.
[0154] According to one embodiment, the stabilizing composition is liquid and comprises a high molecular weight poly(oxyethylene) polymer, preferably polyethylene glycol, at a final concentration of 0.4% to 35% (w / v). Exemplary ranges include, but are not limited to, 0.8% to 25% (w / v), 1.5% to 20% (w / v), 2.5% to 17.5% (w / v), 3% to 15% (w / v), 4% to 10% (w / v), and 3% to 5% (w / v). Suitable concentrations may be determined by one of skill in the art based on the present disclosure and may vary depending, among other things, on whether the high molecular weight poly(oxyethylene) polymer is used alone or in combination with additional poly(oxyethylene) polymers, such as low molecular weight poly(oxyethylene) polymers, and the amount, e.g., volume, of the stabilizing composition used to stabilize a particular amount of urine sample. Examples of suitable concentration ranges for high molecular weight poly(oxyethylene) polymers when used alone include, but are not limited to, 2.2% to 33.0% (w / v), such as 4.4% to 22.0% (w / v), 6.6% to 16.5% (w / v), or 8.8% to 13.2% (w / v). Examples of suitable concentration ranges for high molecular weight poly(oxyethylene) polymers when used in combination with low molecular weight poly(oxyethylene) polymers include, but are not limited to, 0.4% to 30.7% (w / v), such as 0.8% to 15.3% (w / v), 1% to 10% (w / v), 1.5% to 7.7% (w / v), 2.5% to 6% (w / v), 3.1% to 5.4% (w / v), and 3% to 4% (w / v).
[0155] In a specific embodiment, the liquid stabilizing composition comprises 5 mg to 500 mg, particularly 10 mg to 250 mg, 25 mg to 150 mg, or 40 mg to 100 mg of high molecular weight poly(oxyethylene) polymer, which is preferably polyethylene glycol. In particular, the liquid stabilizing composition may comprise 0.5 μmol to 50 μmol, particularly 1 μmol to 25 μmol, 2 μmol to 20 μmol, or 3 μmol to 10 μmol of high molecular weight poly(oxyethylene) polymer. Such liquid stabilizing composition may be filled, for example, into a receiving device, and is suitable, for example, for stabilizing a sample unit urine.
[0156] According to one embodiment, the stabilizing composition comprises a poly(oxyethylene) polymer, which is a poly(oxyethylene) polymer having a molecular weight of 1500 or less, and in embodiments a low molecular weight poly(oxyethylene) polymer having a molecular weight of 1000 or less. The low molecular weight poly(oxyethylene) polymer may have a molecular weight in the range selected from 100 to 1000, such as 150 to 800 or 150 to 700. More preferred is a molecular weight in the range of 200 to 600 and more preferably 200 to 500, such as 200 to 400. Preferably, polyethylene glycol is used.
[0157] According to one embodiment, the liquid stabilization composition comprises a low molecular weight poly(oxyethylene) polymer, preferably polyethylene glycol, at a final concentration selected from 0.8% to 92.0%. Examples include 3.8% to 76.7%, 11.5% to 53.7%, 19.2% to 38.3% and 20% to 35%, such as 20% to 30%. The aforementioned concentrations refer to (w / v) or (v / v) depending on whether the low molecular weight poly(oxyethylene) polymer is liquid or not.
[0158] In a specific embodiment, the liquid stabilizing composition comprises 40 μl to 4000 μl, in particular 100 μl to 2000 μl, 150 μl to 1500 μl, 200 μl to 1000 μl or 250 μl to 750 μl of low molecular weight poly(oxyethylene) polymer. In particular, the liquid stabilizing composition may comprise 0.2 mmol to 15 mmol, in particular 0.5 mmol to 10 mmol, 0.75 mmol to 5 mmol, 1 mmol to 3 mmol, or 1.2 mmol to 2 mmol of low molecular weight poly(oxyethylene) polymer. Such liquid stabilizing composition may, for example, be filled into a receiving device and is suitable for stabilizing, for example, a sample unit.
[0159] According to one embodiment, the stabilizing composition comprises a high molecular weight poly(oxyethylene) polymer and further comprises at least one further poly(oxyethylene) polymer having a molecular weight of at least 100, preferably at least 200, at least 300 or at least 400, less than the molecular weight of the high molecular weight poly(oxyethylene) polymer. The embodiment is also described in conjunction with the method according to the first aspect. According to one embodiment, the difference in molecular weight is at least 2500, at least 3500, at least 5000 or at least 7500. As described above in conjunction with the stabilizing method according to the first aspect, it is advantageous to use a combination of poly(oxyethylene) polymers with different molecular weights. Preferably, both poly(oxyethylene) polymers are polyethylene glycols, such as unsubstituted polyethylene glycols. The stabilizing composition may comprise a high molecular weight poly(oxyethylene) polymer having a molecular weight of at least 1500 and a low molecular weight poly(oxyethylene) polymer having a molecular weight of 1000 or less. The low molecular weight poly(oxyethylene) polymer is preferably a polyethylene glycol, such as unsubstituted polyethylene glycol. The molecular weight of the low molecular weight poly(oxyethylene) polymer may be in a range selected from 100 to 1000, 150 to 800, and is preferably in the range of 200 to 600. Suitable concentration ranges of the high molecular weight poly(oxyethylene) polymer and the low molecular weight poly(oxyethylene) polymer in the stabilizing composition are described above. Preservatives to inhibit bacterial growth
[0160] The stabilized composition in one embodiment comprises a preservative for inhibiting bacterial growth. As disclosed above, this preservative may be used in addition to the chelating agent. Suitable and preferred embodiments are described above in conjunction with the method according to the first aspect, and reference is made to said disclosures which also apply here.
[0161] The preservative is included in the stabilizing composition at a concentration such that bacterial growth is inhibited in the stabilized urine sample. The suitable concentration can be determined by those skilled in the art for each preservative. The final concentration in the stabilizing composition can be, for example, within the range of 0.1 to 5.5% w / v, for example, 0.2 to 3.75% w / v, or within the range of 0.1 to 5.5% v / v, for example, 0.2 to 3.75% v / v.
[0162] According to one embodiment, the preservative may comprise or consist of sodium azide. As demonstrated by the examples, sodium azide is particularly suitable. The stabilized composition may comprise sodium azide at a final concentration of, for example, 0.15% to 3.75% (w / v) or 0.2% to 3.5% (w / v). According to an embodiment, the final concentration in the stabilized composition is 0.3% to 3% (w / v) or 0.3% to 2.5% (w / v).
[0163] Furthermore, the preservative may comprise or consist of at least one isothiazolinone compound, preferably methylchloroisothiazolinone and / or methylisothiazolinone. These compounds may be mixed in a ratio of 3:1. A commercially available preservative for inhibiting bacterial growth that comprises an isothiazolinone compound is ProClin300. As demonstrated by the examples, the preservative is suitable for use in stabilizing urine. It may be included in the stabilizing composition at a final concentration of, for example, 0.2% to 1% (v / v) or 0.3 to 0.5% (v / v), such as 0.375% (v / v).
[0164] Further examples of preservatives that may be used include, but are not limited to, chlorhexidine or sodium borate. Additional preservatives and useful concentrations for inhibiting bacterial growth can be determined by one of skill in the art following the disclosure of the present application. Caspase inhibitors
[0165] According to one embodiment, the stabilized composition comprising a chelating agent and a poly(oxyethylene) polymer further comprises a caspase inhibitor. The advantages of using a caspase inhibitor and suitable and preferred embodiments of the caspase inhibitor have been described in detail above in conjunction with the stabilization method according to the first aspect, and reference is made to the above disclosures which also apply here. Preferably, the caspase inhibitor is a pan-caspase inhibitor. Preferably, the caspase inhibitor is a modified caspase-specific peptide, preferably modified at the C-terminus by an O-phenoxy group, such as Q-VD-OPh. According to an advantageous embodiment, a high molecular weight poly(oxyethylene) polymer having a molecular weight of at least 1500 is used as the poly(oxyethylene) polymer. Preferably, polyethylene glycol is used. Preferably, unsubstituted polyethylene glycol is used.
[0166] According to one embodiment, the stabilizing composition comprises a caspase inhibitor at a concentration of 1 μM to 220 μM, for example 5 μM to 200 μM, 10 μM to 150 μM and 20.0 μM to 100 μM. In a specific embodiment, the stabilizing composition comprises a caspase inhibitor at a concentration of 1 nmol to 1000 nmol, in particular 5 nmol to 500 nmol, 10 nmol to 200 nmol or 25 nmol to 100 nmol. The stabilizing composition is preferably a liquid, which may be filled, for example, into a receiving device and is suitable for stabilizing, for example, a sample unit urine.
[0167] The stabilizing composition may contain further additives as described above in conjunction with the stabilizing method according to the first aspect. According to one embodiment, the composition contains mono-ethylene glycol (1,2-ethanediol) as a stabilizing agent. Mono-ethylene glycol may be used in the concentrations described above for the low molecular weight poly(oxyethylene) polymer. Amide
[0168] According to one embodiment, the stabilization composition further comprises at least one primary, secondary or tertiary amide. Suitable and preferred embodiments are described in detail above in conjunction with the stabilization method according to the first aspect, and reference is made to the above disclosures which also apply here. According to one embodiment, the at least one primary, secondary or tertiary amide contained in the stabilization composition is a compound according to formula 1: [ka] where R1 is a hydrogen or alkyl residue, preferably a C1-C5 alkyl residue, a C1-C4 alkyl residue or a C1-C3 alkyl residue, more preferably a C1-C2 alkyl residue; R2 and R3 are identical or different and are selected from hydrogen and hydrocarbon residues, preferably alkyl residues with a carbon chain length of 1-20 atoms arranged in a linear or branched manner; and R4 is an oxygen, sulfur or selenium residue. Preferably, the amide is a carboxylic acid amide, such that R4 is oxygen. Preferred embodiments are described above in conjunction with the stabilization method, reference being made to the above disclosure which also applies here. Preferably, a compound according to formula 1 is used, which is not classified as a toxic agent. Preferably, said stabilization composition comprising a compound according to formula 1 further comprises a caspase inhibitor.
[0169] The compound according to formula 1 may be a carboxylic acid amide selected from primary carboxylic acid amides and secondary carboxylic acid amides. According to one embodiment, the composition comprises a primary carboxylic acid amide selected from the group consisting of formamide, acetamide, propanamide and butanamide. The carboxylic acid may be selected from butanamide and formamide.
[0170] According to one embodiment, at least one compound according to formula 1 is an N,N-dialkyl-carboxylic acid amide. According to one embodiment, the compound according to formula 1 is an N,N-dialkylpropanamide, preferably N,N-dimethylpropanamide.
[0171] According to one embodiment, the stabilizing composition comprises butanamide and / or N,N-dialkylpropanamide, said N,N-dialkylpropanamide being preferably N,N-dimethylpropanamide. As demonstrated by the examples, both amides, alone or in combination, can support a stabilizing effect.
[0172] According to one embodiment, the stabilizing composition is a liquid composition and comprises one or more primary, secondary or tertiary amides at a concentration selected from 0.4% to 38.3%, for example 0.8% to 23.0%, 2.3% to 11.5% and 3.8% to 9.2%. Further ranges include 5% to 15% and 7.5% to 12.5%. The aforementioned concentrations refer to (w / v) or (v / v) depending on whether the primary, secondary or tertiary amide is liquid or not.
[0173] In a specific embodiment, the liquid stabilizing composition comprises 10 μl to 2000 μl, in particular 50 μl to 1000 μl, 100 μl to 750 μl, or 125 μl to 500 or 150 to 250 μl of a primary, secondary or tertiary amide. In particular, the liquid stabilizing composition may comprise 0.2 mmol to 15 mmol, in particular 0.5 mmol to 10 mmol, 0.75 mmol to 5 mmol, 1 mmol to 3 mmol, or 1.2 mmol to 2 mmol of a primary, secondary or tertiary amide. Such a liquid stabilizing composition may be filled, for example, in a receiving device and is suitable, for example, for stabilizing a sample unit urine. Further embodiments
[0174] Further advantageous embodiments of the stabilised composition according to the first aspect are now described.
[0175] According to one embodiment, the stabilizing composition comprises: - EDTA as a chelating agent, at least one polyethylene glycol, preferably at least one high molecular weight polyethylene glycol having a molecular weight of at least 3000 and / or at least one low molecular weight polyethylene glycol having a molecular weight of 1000 or less, - a preservative to inhibit bacterial growth, - buffering agents, - optionally, at least one caspase inhibitor, and - optionally at least one primary, secondary or tertiary amide Includes.
[0176] According to one embodiment, the stabilizing composition comprises: EDTA, at a concentration of at least 100 mM up to its solubility limit, preferably in the range 150 mM to 500 mM; at least one polyethylene glycol, preferably at least one high molecular weight polyethylene glycol having a molecular weight of at least 6000 and optionally at least one low molecular weight polyethylene glycol having a molecular weight of 1000 or less, - a preservative to inhibit bacterial growth, - Buffering agents, as well as - Optionally, at least one caspase inhibitor A liquid composition comprising: The pH of the stabilizing composition is in the range of more than 7 to 9.5, 7.2 to 9.5, 7.3 to 9.5 or 7.5 to 9.5, and the stabilizing composition is contacted with the urine sample in a volume ratio selected from 1:3 to 1:10, preferably 1:5 to 1:8. The pH of the stabilizing composition may be in the range of 7.2 to 9, 7.2 to 8.75 or 7.3 to 8.5. The final pH in the stabilized urine sample may be in the range of 6 to 9.5, for example 6.3 to 9.5 or 6.5 to 9. As shown by the examples, the use of a stabilizing composition according to this makes it possible, inter alia, to bring about a final pH of the stabilized urine sample in the range of 6.5 to 8.75, for example 6.5 to 8.5. A good stabilizing effect was achieved. The final concentration of EDTA in the urine sample stabilized with the stabilizing composition is preferably in the range of 7 mg / ml to 40 mg / ml, more preferably in the range of 10 mg / ml to 30 mg / ml. Preferred embodiments and concentrations for polyethylene glycol, preservatives and buffers are disclosed above. The stabilized composition may comprise at least one primary, secondary or tertiary amide as disclosed herein. Form of the composition
[0177] The stabilizing composition may be provided in solid form, semi-liquid form, or as a liquid. The advantage of using a solid stabilizing composition is that solids are often more chemically stable. A liquid composition has the advantage that it can be mixed with the sample to be stabilized quickly, thereby essentially providing a stabilizing effect as soon as the urine sample comes into contact with the liquid stabilizing composition. The use of a liquid composition is preferred because it can also adjust the pH of the urine sample. Preferably, the stabilizing agent present in the liquid stabilizing composition remains stable in solution and does not require pretreatment by the user, such as dissolving precipitates with limited solubility.
[0178] The present invention also provides a mixture comprising the stabilizing composition according to the third aspect of the invention mixed with a urine sample. Suitable and preferred concentrations of the stabilizing agent when mixed with the urine sample and in the thus stabilized urine sample are, inter alia, described above in conjunction with the stabilization method according to the invention. Reference is made to the above disclosure which also applies here.
[0179] According to one embodiment, the stabilizing composition of the present invention is pre-filled into a sample receiving device, such as a vacuum tube, so that the sample is immediately stabilized when a urine sample is contained in the receiving device. Details of such a receiving device are disclosed in conjunction with the fifth aspect. According to one embodiment, the liquid stabilizing composition is contacted with the urine sample in a volume ratio selected from 1:3 to 1:10, such as 1:5 to 1:10, 1:5 to 1:8, in particular about 1:6. It is a notable advantage of the stabilizing composition of the present invention that the stabilization of a large volume of sample can be achieved with a small volume of the stabilizing composition. Thus, preferably, the ratio of the stabilizing composition to the sample is in the range of 1:10 to 1:5, in particular 1:7 to 1:5, such as about 1:6. advantage
[0180] The advantages are discussed above in conjunction with the method according to the first aspect, and reference is made to the respective disclosures as they apply here. The stabilizing composition provided by the present invention stabilizes important components of a urine sample, allowing for the subsequent analysis of, for example, cell-free DNA, genomic DNA and / or urine cells.
[0181] In an embodiment, the stabilization composition does not contain additives at a concentration such that said additives induce or promote cell lysis of nucleated cells, preferably cells in general. As demonstrated by the examples, urine cells are stabilized and available for cytological analysis, and intracellular nucleic acids such as genomic DNA can be isolated and analyzed. Preferably, the stabilization composition does not contain cross-linking agents that induce protein-DNA and / or protein-protein cross-linking. In particular, the stabilization composition does not contain formaldehyde, formalin, paraformaldehyde or formaldehyde-releasing agents or similar cross-linking agents. Preferably, the stabilization composition of the present invention is capable of stabilizing urine samples without refrigeration, preferably at room temperature, for a period selected from at least 2 days, at least 3 days, at least 4 days, at least 5 days and / or at least 6 days. In particular, one or more, preferably all, of the above stabilization effects are achieved during the defined stabilization period.
[0182] The stabilizing composition of the present invention can be incorporated into a sample collection device, particularly a urine collection assembly, such as a urine collection cup, thereby providing a new and useful version of such a device. This allows the sample to be stabilized immediately after urine collection. In a further embodiment, the stabilizing composition of the present invention is provided in a receiving device, preferably a vacuum tube, into which already collected urine is transferred after collection. Further details are also disclosed in conjunction with the fifth and sixth aspects. D. Use
[0183] According to a fourth aspect, the present invention is directed to the use of a stabilizing composition according to the third aspect for stabilizing a urine sample. In particular, the stabilizing composition according to the third aspect can be used in a method according to the first aspect of the invention, the details of which are given above and reference is made to the disclosures therein which also apply here. E. Receptor Device
[0184] According to a fifth aspect, the present invention provides a receiving device for receiving a urine sample, comprising: a chelating agent, preferably EDTA, at least one poly(oxyethylene) polymer, preferably polyethylene glycol, and - Optionally, a preservative to inhibit bacterial growth A receiving device is provided, comprising:
[0185] The receiving device is suitable for stabilizing the urine sample. Bacterial growth may be inhibited in the stabilized urine sample. The receiving device may include one or more of the additional stabilizing agents discussed above, such as a caspase inhibitor (preferably a caspase inhibitor specific peptide). At least one primary, secondary or tertiary amide (preferably one or more compounds according to formula 1) may be included. Details are described above, and reference is made to the disclosure above.
[0186] According to a preferred embodiment, the receiving device comprises a stabilised composition according to the third aspect as described in detail above, the disclosure of which also applies here. According to one embodiment, the receiving device comprises a stabilised composition as defined in any one of claims 18 to 24.
[0187] Providing a respective receiving device has the advantage that when a urine sample is transferred into said receiving device, the sample is immediately stabilized. Urine may be collected in a container, such as a urine cup or a pediatric bag, and then transferred into the receiving device for stabilization. Alternatively, urine is collected directly into the receiving device. The receiving device may be used in the method according to the first aspect for stabilization. The receiving device may be provided by a container, preferably a vacuum tube. Chelating Agents
[0188] The receiving device comprises a chelating agent, preferably EDTA. Suitable chelating agents and concentrations in the stabilized urine have been described above in conjunction with the method according to the first aspect, reference being made to said disclosure which also applies here. According to one embodiment, the container comprises a chelating agent, preferably EDTA, in a concentration such that when the urine sample is collected in the receiving device, the final concentration of the chelating agent in the mixture subsequently obtained with the urine contained in the receiving device, i.e. in the stabilized urine, is at least 4 mg / ml, at least 5 mg / ml or at least 7 mg / ml. It is advantageous to use a chelating agent, such as preferably EDTA, in a higher concentration to stabilize the urine in order to achieve a stronger stabilizing effect. Thus, in an embodiment, the final concentration of the chelating agent, preferably EDTA, in the stabilized urine sample is at least 7 mg / ml, preferably at least 10 mg / ml. In the examples, a concentration of at least 15 mg / ml was used. According to one embodiment, the final concentration in the stabilized urine sample is in the range of 10 mg / ml to 35 mg / ml or 10 mg / ml to 30 mg / ml. Final concentrations ranging from 12 mg / ml to 30 mg / ml or 15 mg / ml to 25 mg / ml are also suitable. In the examples, a receiving device was used containing EDTA at a concentration such that a final concentration of EDTA in the stabilized urine during urine collection was achieved in the range of 15 mg / ml to 20 mg / ml. Poly(oxyethylene) polymer
[0189] The receiving device comprises a poly(oxyethylene) polymer, preferably polyethylene glycol. Suitable and preferred embodiments are described above in conjunction with the method according to the first aspect, reference being made to said disclosure which also applies here.
[0190] According to one embodiment, a high molecular weight poly(oxyethylene) polymer is included in the device. In one embodiment, a high molecular weight poly(oxyethylene) polymer, preferably polyethylene glycol, is included in the receiving device at a concentration such that when a urine sample is collected in the device, the final concentration of high molecular weight poly(oxyethylene) polymer in the resulting mixture is within the range of 0.05% to 5% (w / v). Suitable ranges include, but are not limited to, 0.1% to 4% (w / v), 0.2% to 3% (w / v), 0.25% to 2.5% (w / v), 0.3% to 2% (w / v), and preferably 0.35% to 1.5% (w / v). According to one embodiment, the high molecular weight poly(oxyethylene) polymer is included in the receiving device at a concentration such that when a urine sample is collected in said device, the final concentration of high molecular weight poly(oxyethylene) polymer in the resulting mixture is within the ranges of 0.2% to 1.5% (w / v), 0.25% to 1.25% (w / v), 0.3% to 1% (w / v) and 0.4% to 0.75% (w / v).
[0191] According to one embodiment, the receiving device comprises a low molecular weight poly(oxyethylene) polymer having a molecular weight of 1000 or less. The low molecular weight poly(oxyethylene) polymer may have a molecular weight in the range selected from 100 to 1000, 150 to 800 and 150 to 700. Preferably, the molecular weight is in the range of 200 to 600, more preferably 200 to 500, for example 200 to 400. According to one embodiment, the low molecular weight poly(oxyethylene) polymer is advantageously included in the receiving device in a concentration such that when a urine sample is collected in said device, the final concentration of the low molecular weight poly(oxyethylene) polymer in the resulting mixture is in the range of 0.5% to 10%, 1.5% to 9%, 2% to 8% and 2.5% to 7% and 3% to 6%. The percentage values refer to (w / v) when the poly(oxyethylene) polymer is solid and (v / v) when the poly(oxyethylene) polymer is liquid. Preferably, the poly(oxyethylene) polymer is polyethylene glycol.
[0192] According to one embodiment, the receiving device comprises a high molecular weight poly(oxyethylene) polymer as defined above having a molecular weight of at least 1500 and a low molecular weight poly(oxyethylene) polymer having a molecular weight of 1000 or less, such that when urine is added to the receiving device, the urine sample contacts both types of poly(oxyethylene) polymer. Suitable and preferred embodiments and advantages associated with this embodiment in which a high molecular weight poly(oxyethylene) polymer is used in combination with a low molecular weight poly(oxyethylene) polymer have been described in detail above, and reference is made to the respective disclosures which apply here as well.
[0193] In an advantageous embodiment, the receiving device comprises a high molecular weight poly(oxyethylene) polymer and a low molecular weight poly(oxyethylene) polymer in concentrations such that when a urine sample is collected in said device, the concentration of the high molecular weight poly(oxyethylene) polymer in the resulting mixture is within the ranges of 0.2% to 1.5% (w / v), 0.3% to 1.25% (w / v) and 0.4% to 0.75% (w / v) and the concentration of the low molecular weight poly(oxyethylene) polymer is within the ranges selected from 1.5% to 8%, 2% to 7% and 2.5% to 6%. Preferably, the high molecular weight poly(oxyethylene) polymer and the low molecular weight poly(oxyethylene) polymer are polyethylene glycols as described above.
[0194] According to one embodiment, the mixture obtained after contacting the urine sample with the high molecular weight poly(oxyethylene) polymer and the low molecular weight poly(oxyethylene) polymer and, if necessary, with further additives used for stabilization, comprises a high molecular weight poly(oxyethylene) polymer, which may have, for example, a molecular weight in the range of 4000 to 20000, at a final concentration lying within the range of 0.15% to 1.5%, for example 0.2% to 1% (w / v), preferably 0.25% to 0.75% (w / v), for example 0.5% (w / v), and a low molecular weight poly(oxyethylene) polymer, preferably with a molecular weight in the range of 200 to 800, preferably 200 to 600, at a final concentration lying within the range selected from 1.5% to 8%, preferably 2% to 7%, more preferably 2.5% to 6%. Polyethylene glycol, preferably unsubstituted polyethylene glycol, is preferably used as the high molecular weight poly(oxyethylene) polymer and as the low molecular weight poly(oxyethylene) polymer. Suitable embodiments relating to high and low molecular weight poly(oxyethylene) polymers are also described above and in conjunction with the different aspects and embodiments disclosed herein. Preservatives to inhibit bacterial growth
[0195] The receiving device may further comprise a preservative to inhibit bacterial growth. The preservative is used in addition to the chelating agent. Suitable and preferred embodiments of the preservative are described above in conjunction with the method according to the first aspect, reference being made to said disclosure which also applies here.
[0196] The preservative is included in an amount such that bacterial growth is inhibited in the stabilized urine sample. Suitable concentrations can be determined by one of skill in the art for each particular preservative.
[0197] A preservative may be included in the stabilised composition according to the third aspect, which may be included in the receiving device, and the final concentration in the stabilised composition may be, for example, in the range of 0.1 to 5.5% w / v, such as 0.2 to 3.75% w / v, or in the range of 0.1 to 5.5% v / v, such as 0.2 to 3.75% v / v.
[0198] According to one embodiment, the preservative may comprise or consist of sodium azide. As demonstrated by the examples, sodium azide is particularly suitable. The stabilizing composition contained in the receiving device may comprise sodium azide, for example, at a final concentration of 0.15% to 3.75% (w / v) or 0.2% to 3.5% (w / v). According to an embodiment, the final concentration in the stabilizing composition is 0.3% to 3% (w / v) or 0.3% to 2.5% (w / v).
[0199] Furthermore, the preservative may comprise or consist of at least one isothiazolinone compound, preferably methylchloroisothiazolinone and / or methylisothiazolinone. These compounds may be mixed in a ratio of 3:1. A commercially available preservative for inhibiting bacterial growth that comprises an isothiazolinone compound is ProClin300. As demonstrated by the examples, the preservative is suitable for use in stabilizing urine. The preservative may be included in the stabilizing composition contained in the receiving device at a final concentration of, for example, 0.2% to 1% (v / v) or 0.3% to 0.5% (v / v), such as 0.375% (v / v).
[0200] Further examples of preservatives that may be used include, but are not limited to, chlorhexidine or sodium borate. Additional preservatives and useful concentrations for inhibiting bacterial growth can be determined by one of skill in the art following the disclosure of the present application.
[0201] The preservative may be included in the receiving device in a concentration such that when the urine sample is collected in the receiving device, the final concentration of the preservative in the resulting mixture, i.e. the stabilized urine, may be in the range of 0.01 to 0.7% w / v, such as 0.03 to 0.5% w / v, or in the range of 0.01 to 0.7% v / v, such as 0.03 to 0.5% v / v. Suitable concentrations and embodiments for the preservative in the stabilized urine sample are also disclosed in conjunction with the method according to the first aspect, and reference is made to this disclosure which also applies here. Caspase inhibitors
[0202] In one embodiment, at least one caspase inhibitor is further comprised in the receiving device. Suitable and preferred embodiments are described above in conjunction with the method according to the first aspect, reference being made to said disclosure which also applies here.
[0203] The caspase inhibitor may be included in a concentration such that when the urine sample is collected in the receiving device, the final concentration of the caspase inhibitor in the resulting mixture, i.e., stabilized urine, is at least 0.5 μM or at least 1 μM, for example at least 1.5 μM, at least 2 μM or at least 2.5 μM. Suitable final concentration ranges for the caspase inhibitor when mixed with the urine sample and further additives include, but are not limited to, 1 μM to 25 μM, 1.5 μM to 20 μM and 2 μM to 15 μM. Final concentration ranges of 2 μM to 12.5 μM, 2.5 μM to 10 μM and 3 μM to 7.5 μM are preferred. This may be within the range of 0.1 μM to 20 μM, more preferably 0.5 μM to 10 μM, more preferably 1 μM to 10 μM, more preferably 3 μM to 7.5 μM or 3 μM to 5 μM. According to one embodiment, at least one primary, secondary or tertiary amide is further used, as described above. Amide
[0204] In one embodiment, at least one primary, secondary or tertiary amide is included in the receiving device. Suitable and preferred embodiments are described above in conjunction with the method according to the first aspect, and reference is made to the disclosure above that also applies here. The amide may be used at a concentration such that when a urine sample is collected in said device, the final concentration of the amide (or combination of amides) in the resulting mixture, i.e., stabilized urine, is in the range of at least 0.05%. For example, the final concentration may be at least 0.1%, at least 0.25%, at least 0.5% or at least 0.75%. Suitable concentration ranges include, but are not limited to, 0.1% to 10%, 0.25% to 7.5%, 0.3% to 5%, 0.4% to 3%, 0.5% to 2%, 0.6% to 1.8% or 0.75% to 1.5%. Concentrations or concentration ranges given as percentage values, as used herein, are given in particular as weight percentage per volume (w / v) for solid amides and as volume percentage per volume (v / v) for liquid amides.
[0205] The at least one amide is preferably a compound according to formula 1 [ka] where R1 is a hydrogen or alkyl residue, preferably a C1-C5 alkyl residue, a C1-C4 alkyl residue or a C1-C3 alkyl residue, more preferably a C1-C2 alkyl residue, R2 and R3 are identical or different and are selected from hydrogen and hydrocarbon residues, preferably alkyl residues with a carbon chain length of 1 to 20 atoms arranged in a linear or branched manner, and R4 is an oxygen, sulfur or selenium residue. Preferably, the amide is a carboxylic acid amide, such that R4 is oxygen. Preferred embodiments of the compound according to formula 1 are described above in conjunction with the stabilization method, and reference is made to the above disclosure which also applies here. According to one embodiment, the receiving device comprises, as the compound according to formula 1, butanamide and / or N,N-dialkylpropanamide, preferably N,N-dimethylpropanamide.
[0206] According to one embodiment, the receiving device contains mono-ethylene glycol as a stabilizing agent, which may be used in the concentrations described above for the low molecular weight poly(oxyethylene) polymers, the respective disclosures of which are again referred to. pH
[0207] As demonstrated in the examples, the pH influences the outcome of the stabilization.
[0208] According to one embodiment, the stabilizing composition contained in the receiving device has a pH in the range of 4.5 to 9.5. Preferably, the pH of the stabilizing composition is in the range of more than 7 and not more than 9.5. The pH may be in the range of 7.2 to 9.5, 7.3 to 9.5 or 7.4 to 9.5. The pH of the stabilizing composition may also be not more than 9.25, not more than 9 or not more than 8.75, such as not more than 8.5, not more than 8.3 or not more than 8. These pH values may be combined with the previously indicated pH ranges as upper limits, the resulting ranges also forming part of the present disclosure. In one embodiment, the pH of the stabilizing composition is in the range of 7.5 to 9.5 or not more than 7.5 or not more than 9.5. In one embodiment, the pH of the stabilizing composition is in the range of 7.2 to 8.5 or not more than 7.3 or not more than 8.3 or not more than 7.5 to 8. The pH of the stabilizing composition may further be in the range of 7.7 to 9.5 or 8 to 9.25. According to a further embodiment, also shown in the examples, the pH of the stabilizing composition is in the basic range of 8 to 9.
[0209] The stabilizing composition preferably comprises a suitable buffering agent that allows to maintain the pH within the desired range when the urine sample is added. Preferred embodiments regarding the pH range of the stabilized urine sample are described above in conjunction with the method according to the first aspect to which reference is made, and the important influence of pH on the stabilization outcome.
[0210] According to one embodiment, the stabilizing composition is a liquid composition and the receiving device is designed (e.g., depressurized) to contact the liquid composition with the received urine sample at a volume ratio selected from 1:3 to 1:10, preferably 1:5 to 1:10. A particular advantage of the teachings of the present invention is that stabilization and pH adjustment of a large volume of urine can be achieved with a small volume of the stabilizing composition according to the present invention. Preferably, the ratio of stabilizing composition to sample is in the range of 1:5 to 1:8, e.g. about 1.6. For example, 1-2 ml of the liquid stabilizing composition may be contacted with approximately 10 ml of urine.
[0211] As demonstrated by the examples, the higher the pH value, the more efficient the cell-free DNA is preserved, because the degradation of cell-free DNA is more effectively prevented compared with acidic pH.This is very advantageous when the cell-free DNA contained in urine sample is intended to be analyzed.As can be seen from the examples, the higher pH, especially basic pH, effectively prevents the degradation of cell-free DNA, even when stabilized urine sample is stored for several days.
[0212] The stabilizing composition includes a buffer for pH adjustment. The buffer may have its pK in the basic range. A suitable and preferred buffer is Tris, as demonstrated by the examples. Other buffers include, but are not limited to, MOPS, TES, HEPES, TAPSO, Tricine, Bicine, TAPS, borate buffers, CHES buffers, or buffers based on sodium or potassium phosphate. Further buffers include carbonates. The pH of urine can vary from acidic to basic depending on the donor and also on the donor's condition. Thus, it is advantageous to include a sufficient concentration of buffer to achieve efficient pH adjustment and stabilization, despite the possibility of pH fluctuations in the collected urine sample to be stabilized. Suitable concentrations can be determined by those skilled in the art.
[0213] According to one embodiment, the final pH of the stabilized urine sample contained in the receiving device is in the range of 6 to 9.5, for example 6.3 to 9.5. The final pH of the stabilized urine sample may be 9 or less, for example 8.75 or less or 8.5 or less. A pH in the stabilized urine sample in the range of 6.5 to 9, for example 6.5 to 8.75 or 6.5 to 8.5, is particularly preferred. In an embodiment, the pH of the stabilized urine sample is in the range of 6.7 to 9 or 7 to 9, for example 7.2 to 9 or 7.2 to 8.75. According to one embodiment, the final pH of the stabilized urine sample is at least 7 or more than 7, and may be in the range of 7.5 to 8.5. Further embodiments
[0214] The stabilizing composition and / or the individual compounds used for stabilization contained in the receiving device may be provided in liquid; semi-liquid or dry form. The compounds used for stabilization may be provided as separate entities in the receiving device or in different forms in the receiving device. For example, one component may be provided in dry form, while the other compound may be provided as liquid. Other combinations are also feasible. Suitable formulations and manufacturing options are known to those skilled in the art. As discussed above, the core stabilizing compound and also the further additives used for stabilization may be provided in the receiving device in the form of a stabilizing composition, preferably a stabilizing composition according to the third aspect, such as the stabilizing composition defined in claims 18 to 24.
[0215] The advantage of using a solid stabilizing composition is that solids are more chemically stable than liquids. According to one embodiment, the inner wall of the receiving device is treated / coated with the stabilizing composition according to the invention or its individual components, such as EDTA. The composition or components can be applied to the inner wall, for example, using a spray drying method. A liquid removal technique can be performed on the stabilizing composition to obtain a substantially solid state protective composition. The liquid removal conditions can be such that they result in the removal of at least about 50% by weight, at least about 75% by weight, or at least about 85% by weight of the original amount of the dispensed liquid stabilizing composition. The liquid removal conditions can be such that they result in the removal of sufficient liquid so that the resulting composition is in the form of a film, gel, or other substantially solid or highly viscous layer. For example, the conditions can result in a substantially immobile coating, preferably a coating that can be dissolved again or otherwise dispersed when contacted with a urine sample. Freeze-drying or other techniques can be used to achieve a substantially solid form of the protective agent, for example, in the form of one or more pellets. Thus, the liquid removal conditions can be such that, upon contact with a urine sample, the protectant disperses into the sample, resulting in a material that substantially preserves components in the sample (e.g., extracellular nucleic acids). The liquid removal conditions can be such that they result in a remaining composition that is substantially free of crystallinity, has a sufficiently high viscosity such that the remaining composition is substantially immobile at ambient temperature, or both.
[0216] According to a preferred embodiment, the receiving device comprises a liquid stabilizing composition. The liquid composition has the advantage that it can achieve rapid mixing with the urine sample to be stabilized, thereby essentially bringing about a stabilizing effect immediately when the urine sample is brought into contact with the liquid stabilizing composition. Furthermore, a liquid composition is advantageous when a large amount of stabilizing composition is used, thereby making it impossible or difficult to spray-dry, or when the composition interferes with providing a dry composition. Preferably, the stabilizing agent present in the liquid stabilizing composition remains stable in solution and does not require pretreatment by the user, such as dissolving precipitates at the solubility limit, because this type of pretreatment brings about the risk of fluctuations in stabilizing efficiency.
[0217] The stabilizing composition is contained in the receiving device in an amount effective to bring about stabilization of the amount of urine sample received by the receiving device. According to one embodiment, the liquid stabilizing composition is contacted with the urine sample in a volume ratio selected from 10:1 to 1:20, 5:1 to 1:15, 1:1 to 1:10, 1:10 to 1:5 and 1:7 to 1:5, in particular about 1:6. A particular advantage of the stabilizing composition of the present invention and the receiving device containing such a stabilizing composition is that the stabilization of a large volume of sample can be achieved with a small volume of the stabilizing composition. Thus, preferably, the ratio of liquid stabilizing composition to urine sample is in the range of 1:10 to 1:5, in particular 1:7 to 1:5, for example about 1:6. The embodiments are also described above, and reference is made to the disclosure which also applies here.
[0218] According to one embodiment, the receiving device is depressurized. The depressurization is preferably effective to draw inward a certain volume of the urine sample previously collected in the urine collection cup. This ensures that a precise amount of urine is contacted with the prefilled amount of stabilizing agent contained in the receiving device, and thus that the stabilization is efficient. According to one embodiment, the receiving device comprises a tube with an open end sealed with a stopper. For example, the receiving device is prefilled with a defined amount of stabilizing composition in solid or liquid form, provided with a defined vacuum, and sealed with a stopper. The stopper is constructed to fit standard sampling accessories (such as a cannula). For example, when contacted with urine by a transfer device (such as a tube), the vacuum collects a predetermined amount of urine in the receiving device. According to one embodiment, the receiving device is for receiving a volume of urine in the range of 5 ml to 20 ml, preferably 7 to 15 ml, for example 10 ml.
[0219] The receiving device according to the invention may be made of glass, plastic or other suitable material. The plastic material may be an oxygen impermeable material or may contain an oxygen impermeable layer. Alternatively, the receiving device may be made of an air permeable plastic material. The receiving device may be made of a transparent material. Examples of suitable transparent thermoplastic materials include polycarbonate, polyethylene, polypropylene and polyethylene terephthalate. The receiving device may have suitable dimensions selected according to the required volume of urine sample to be received. As mentioned above, preferably the receiving device is depressurized to an internal pressure below atmospheric pressure. The pressure is preferably selected to draw a predetermined volume of urine sample into the receiving device.
[0220] According to one embodiment, the receiving device has an open top, a bottom, and a sidewall extending therebetween defining a chamber. A chelating agent (preferably EDTA), a poly(oxyethylene) polymer (preferably polyethylene glycol), a preservative for inhibiting bacterial growth, and optionally one or more additional stabilizing agents as described above or a stabilizing composition according to the third aspect may be included in the chamber. The stabilizing composition may be included in the chamber in liquid or solid form. According to one embodiment, the stabilizing composition is liquid. According to one embodiment, the receiving device is a tube, the bottom is a closed bottom, the receiving device further comprises a stopcock at the open top, and the chamber is under reduced pressure. The advantages of a reduced pressure in the chamber are described above. Preferably, the stopcock is capable of being penetrated by a needle or cannula, and the reduced pressure is selected to draw a specific volume of the liquid sample into the chamber. According to one embodiment, the chamber is under a reduced pressure selected to draw a specific volume of the urine sample into the chamber, and the stabilizing composition is liquid and disposed within the chamber such that the volume ratio of the stabilizing composition to the specific volume of the urine sample is selected from 10:1 to 1:20, 5:1 to 1:15, and 1:1 to 1:10, preferably 1:10 to 1:5, more preferably 1:7 to 1:5. Related advantages are described above.
[0221] According to one embodiment, the receiving device is for receiving 10 ml of urine. According to one embodiment, the stabilizing composition is liquid and has a volume of 2 ml or less, which may be in the range of 0.5 ml to 2 ml, 0.75 ml to 1.75 ml, and 1 ml to 1.7 ml. F. Methods for Collecting Urine Samples
[0222] According to a sixth aspect, there is provided a method comprising collecting a urine sample.
[0223] According to one embodiment, the urine sample is collected in a chamber of a receiving device according to the fifth aspect of the invention, the receiving device preferably comprising a stabilizing composition according to the third aspect. Details regarding the receiving device, the stabilizing composition and the stabilized urine sample are described above. Reference is made to the respective disclosures.
[0224] Urine may be initially collected in a urine cup or other container prior to stabilization. Thus, according to one embodiment, the present invention provides a method for collecting a urine sample, comprising: a) collecting urine in a container, preferably a urine cup; and b) stabilising the urine sample using the method according to the first aspect The present invention provides a method comprising:
[0225] In step a), a urine sample is collected from a donor in a container. Containers suitable for collecting urine are known in the art and are widely used for urine collection from donors. The container may be, for example, a urine cup or a pediatric bag. In one embodiment, the container comprises one or more stabilizing agents in a dry form, preferably in a spray-dried form. This provides the advantage that an initial stabilizing effect is already achieved during the first urine collection. The urine dissolves the dry stabilizing agent.
[0226] According to one embodiment, the container used in step a) contains a chelating agent, preferably EDTA or the like. The chelating agent may be incorporated in the spray-dried form. Incorporating a chelating agent, such as EDTA, into the container used for the initial urine collection, such as a urine cup, provides the additional advantage that the final concentration of the chelating agent in the stabilized (i.e. after performing step b)) urine sample can be increased.
[0227] In step b), the collected urine sample is then stabilized using the method according to the first aspect of the invention as described in detail above, in particular by using the method according to any one of claims 1 to 15. The transferred urine sample may already contain dissolved stabilizing agent(s) if such agent(s) were incorporated during step a), e.g. EDTA.
[0228] The urine collected in step a) may be transferred in step b) into a receiving device according to the fifth aspect for stabilization, where the receiving device preferably comprises a stabilization composition according to the third aspect, such as a stabilization composition as defined in any one of claims 18 to 24. The receiving device used in step b) is preferably a vacuum tube for receiving a defined amount of urine sample. This allows a defined volume to be stabilized in step b). The stabilization composition is preferably a liquid composition. Details are described above and reference is made to the above disclosure.
[0229] After stabilization in step b), the stabilized urine sample may be further processed, for example as disclosed in conjunction with the method according to the second aspect, reference being again made to the respective disclosures which apply. G. Manufacturing method
[0230] According to a seventh aspect, there is provided a method of producing a stabilised composition according to the third aspect of the invention, in which the components of the stabilised composition are combined, preferably mixed, to provide a liquid solution.
[0231] The present invention is not limited to the exemplary methods and materials disclosed herein, and any methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the present invention. Numerical ranges are inclusive of the numbers defining the range. The headings provided herein are not limitations of the various aspects or embodiments of the present invention, but rather can be read with reference to the specification as a whole.
[0232] Unless the context indicates otherwise, the percentage values indicated herein refer to (w / v) in the case of solid compounds contained in a liquid mixture or composition and (v / v) in the case of liquid compounds contained in a liquid mixture or composition, such as, for example, a mixture obtained by contacting a stabilizing agent or a stabilized composition containing said agent with a urine sample.
[0233] As used in the subject specification, the singular forms "a," "an," and "the" include plural embodiments unless the context clearly dictates otherwise. Thus, for example, a reference to "a poly(oxyethylene) polymer" includes a singular type of poly(oxyethylene) polymer, as well as two or more poly(oxyethylene) polymers. Similarly, a reference to an "agent," an "additive," a "compound," etc. includes a singular entity as well as combinations of two or more such entities. References to "the disclosure," "the invention," etc. include single or multiple embodiments, etc., taught herein. The embodiments taught herein are encompassed by the term "invention."
[0234] The term "solution" as used herein refers in particular to a liquid composition, preferably an aqueous composition. The solution may be a homogeneous mixture of only one phase, but it is also within the scope of the present invention that the solution contains solid additives, such as, for example, precipitates of chemicals contained therein, in particular stabilizers.
[0235] The terms "stabilization composition" and "stabilizing composition" are used synonymously herein.
[0236] The sizes and size ranges given herein in relation to nucleotides (nt) each refer to the chain length and are therefore used to describe the length of single-stranded and double-stranded molecules, in which the nucleotides are paired.
[0237] As used herein, the term "comprising" should be interpreted as embracing both "including" and "consisting of," both meanings being specifically intended and therefore individually disclosed embodiments according to the present invention. According to one embodiment, the subject matter described herein as comprising a particular step in the case of a method, or as comprising a particular component in the case of a composition, solution and / or buffer, refers to the subject matter consisting of each step or component. It is preferred to select and combine the preferred embodiments described herein, and the specific subject matter resulting from each combination of the preferred embodiments also belongs to the present disclosure.
[0238] This application is filed in accordance with application EP 1999, the contents of which are incorporated herein by reference in their entirety. 150 438.0. EXAMPLES
[0239] It should be understood that the following examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.
[0240] Abbreviations used cfDNA: cell-free DNA PEG: Polyethylene glycol EDTA: Ethylenediaminetetraacetic acid DMPA: Dimethylpropionamide DEGMEA: Diethylene glycol-monoethylether-acetate PBS: Phosphate-buffered saline
[0241] I. Experimental Procedure 1. Urinary stabilization Unless otherwise stated, urine was collected in 200 ml bottles. 10 ml of urine was added to 1.7 ml of (i) a stabilizing composition; (ii) PBS, (iii) EDTA solution, and mixed within 15 minutes of urine collection, or (iv) was kept unstabilized.
[0242] The urine and reagents were mixed by inverting the tube 10 times. Stabilized and non-stabilized urine samples were stored upright at room temperature. Table 1 gives an overview of the stabilization compositions (reagents) used and the characteristics of the stabilized urine samples: [Table 1-1] [Table 1-2] 2. Urine disposal
[0243] Unless otherwise stated, urine samples were processed by centrifugation at 1,900×g for 15 min at ambient temperature. Cell-free supernatants were transferred to new centrifuge tubes. Cell pellets were resuspended in PBS and used for cytocentrifugation on glass slides for gDNA isolation and / or cytological staining.
[0244] The supernatant was centrifuged a second time for 10 minutes at 1.900×g. The supernatant from the second centrifugation was transferred to a new tube and either used directly for cell-free DNA purification or stored at −20° C. until use. 3. Manual Purification of gDNA
[0245] Up to 200 μl from the resuspended cell pellet from the first centrifugation of urine was used to purify genomic DNA using the QIAamp Mini kit (QIAGEN). The resuspended pellet was mixed with lysis buffer AL, incubated with proteinase K, ethanol was added to adjust binding conditions, loaded onto a silica membrane, washed twice, and eluted with buffer AE according to the handbook.
[0246] DNA yield was measured with Nandrop (Thermo-Fisher). Integrity was analyzed by agarose gel electrophoresis. 400 ng of genomic DNA was purified using the lambda Hind The gels were loaded onto a 1.5% TAE gel containing III marker, separated at 100 V (150 mA) for 2 h, and stained with ethidium bromide. 4. Cytological analysis of cells in urine
[0247] Up to 100 μl of resuspended urinary cell pellet was loaded into an EZ Funnel and centrifuged directly onto a microscope slide using a Cytospin 4 cytocentrifuge (Shandon). Slides were air-dried for a few seconds and used for staining with Papanicolaou (nuclear staining with Papanicolaou hematoxylin for 1 min, keratin staining with Papanicolaou Lsg OG6(2a) for 3 min, and cytoplasmic staining with Papanicolaou Lsg EA50 for 3 min) or H&E staining using kits or staining reagents from Merck (hematoxylin for 30 sec and eosin for 1 min). 4. Purification of Cell-free DNA
[0248] Cell-free DNA from 4-4.8 ml of stabilized or unstabilized urine was isolated using the QIAsymphony PAXgene Blood ccfDNA Kit protocol. The urine was mixed with proteinase K, binding buffer and magnetic beads by the QIAsymphony robot. The beads with bound DNA were washed three times and the DNA was eluted using 60 μl of elution buffer. 5. Quantitative Real-time PCR Assay and Calculation of 18s rDNA Copies
[0249] To measure the amount of cell-free DNA, a real-time PCR assay was performed with 8 μl of eluate on an Abi Prism HT7900 (Life technologies). In an assay volume of 20 μl, two fragments of the human 18S rDNA gene were amplified in a multiplex PCR using QuantiTect Multiplex PCR Kit reagents (QIAGEN GmbH). Global quantification was achieved by comparison with a standard curve made with human genomic DNA samples equivalent to 10.000 for 10 copies of the human 18s rDNA gene. [Table 2-1] Table 2: DNA target sequences detected by real-time PCR
[0250] Quantification of the 66 bp fragment was used to reflect the total amount of 18S rDNA copies in urine. Quantification of the 500 bp was used to determine the amount of 18S rDNA copies derived from apoptotic urinary cells or mechanically lysed urinary cells. Cell-free DNA in urine has a typical length of 60-170 bp. Therefore, the 500 bp fragment can be considered to be derived from apoptotic urinary cells, lysed urinary cells, or otherwise destroyed urinary cells. 6. Quantitative real-time PCR assay for the Y chromosome DSY14 gene
[0251] To measure cell-free DNA degradation, the relative yield of male cell-free DNA spiked into female samples was analyzed. Real-time PCR assays with RotorGene Q (QIAGEN GmbH) were performed with 8 μl of eluate. In an assay volume of 20 μl using QuantiTect Multiplex PCR Kit reagents (QIAGEN GmbH), a single 66 bp fragment of the human Y chromosome DYS14 gene was amplified in real-time PCR. [Table 4] II. Implemented Examples 1. Example 1 Stabilization of DNA in urine
[0252] Four female and two male donors collected 200 ml of urine each. Aliquots of 10 ml urine were mixed with 1.7 ml of PBS or stabilizer within 15 min after sampling. After urine processing, DNA was isolated from cell-free samples on a QIAsymphony either immediately after mixing with the reagents (t0) or after 4 days of incubation at room temperature. All samples were processed in duplicate. 18s rDNA copy numbers were determined from duplicate samples by real-time PCR in triplicate. Results for the 66 bp fragment are shown in Figure 1 and for the 500 bp fragment in Figure 2. Discussion
[0253] This result demonstrates that cell-free DNA degrades rapidly in unstabilized urine, i.e. urine buffered with PBS. The release of DNA from apoptotic or lysed cells cannot be monitored in unstabilized urine (PBS), especially since it degrades rapidly even at time 0. Both processes, the degradation of cell-free DNA and the release of DNA from cells, seem to occur simultaneously. Thus, the degradation of cell-free DNA may be even more severe in PBS than already shown in Figure 2. The total amount of cell-free DNA, which is a small molecule, is preserved in urine stabilized with the reagent according to the present disclosure, as well as large molecules. 2. Example 2 Sampling of urine into BD Vacutainer Urine Collection Cups and transfer to different vacutainers containing different stabilizing reagents
[0254] Urine from one male donor was centrifuged twice to remove all cells from the urine for spiking in the female urine. Urine was collected in larger bottles from two female and two male donors. In the case of the two female donors, 25 ml was centrifuged, thus adding cell-free male urine to 200 ml of female urine. Approximately 120 ml of urine from each donor was loaded into a BD Vacutainer Urine Collection Cup. Urine was transferred from the cup into two spray-dried EDTA tubes per donor: one PAXgene Blood ccfDNA tube and one Streck cell-free DNA BCT tube. One of the EDTA tubes per donor was opened and 1.7 ml of stabilizing reagent R1 was added. All tubes were carefully inverted five times to mix the urine with the components.
[0255] Cell-free DNA was then purified on a QIAsymphony either immediately after collection (t0) or after 1, 3 and 9 days of incubation at room temperature. 18s rDNA copy numbers were determined from duplicate samples by real-time PCR in triplicate. Relative yields of Y chromosome DYS14 DNA were determined from duplicate samples by real-time PCR (no PCR replicates). Results are shown in Figures 3 and 4. Discussion
[0256] This example shows that the BD Vacutainer Urine Collection Cup can be integrated into the urine workflow. Furthermore, the data show that EDTA alone does not adequately prevent cell-free DNA degradation over the storage period (Figure 4) nor does it prevent the increase in total DNA in urine due to DNA release from cells (Figure 3). In contrast, the PAXgene Blood ccfDNA Tube, intended for use with blood samples, stabilizes total and cell-free DNA in urine for up to 3 days. After 9 days, there is an increase in total DNA and a decrease in spiked-in cell-free DNA.
[0257] While the Streck cfDNA BCT reasonably stabilizes total DNA in urine, it also results in a reduction of spiked-in cell-free DNA, similar to K2-EDTA, demonstrating that the original cell-free DNA is degraded and DNA is released from cells during the stabilization period (see Figures 3 and 4 combined).
[0258] We demonstrate that the stabilization reagent (R1) according to the invention added to urine collected in K2-EDTA tubes efficiently stabilizes DNA yields and preserves the male DYS14 copies spiked into female urine, thereby efficiently preventing / reducing cell-free DNA degradation as well as the release of genomic DNA from cells. These beneficial results were maintained over extended stabilization periods. 3. Example 3 Multicomponent testing performed on one urine sample
[0259] 200 ml of urine was collected from each of the three donors. Aliquots of 10 ml of urine were mixed with 1.7 ml of Reagent R1 within 15 min after sampling or kept unstabilized. Samples were processed immediately or stored at room temperature for 3 and 7 days. For processing, samples were centrifuged at 1900×g for 15 min. The supernatant was centrifuged again (1900×g for 10 min) and the supernatant from the second centrifugation was used for duplicate purification of cell-free DNA on a QIAsymphony system. The cell pellet obtained after the first centrifugation was dissolved in 300 μl of PBS. 200 μl of the resuspended cell pellet was used for extraction of genomic DNA using the QIAamp Blood Mini kit. The remaining 100 μl was centrifuged on a glass slide and stained with Papanicolaou (see FIG. 7). The copy number of 18s rDNA in ccfDNA was determined from duplicate samples by real-time PCR in triplicate. Genomic DNA yields were measured using a Nanodrop instrument, and the results are shown in Figures 5 to 7. Discussion
[0260] Multi-modality testing, including testing for cell-free DNA and genomic DNA as well as conventional cytological staining, is possible on urine samples stabilized by the techniques according to the invention.
[0261] Cell-free DNA degrades rapidly in unstabilized urine, but is preserved in urine stabilized by the present invention. In unstabilized urine, genomic DNA yield may be dramatically reduced after storage. This is avoided by the method of the present invention. Furthermore, in unstabilized urine cells, cytological properties may be destroyed after storage. However, when using the technology according to the present invention, cytological properties are preserved. 4. Example 4 Effect of pH on the preservation of cell-free (cf)DNA in urine
[0262] Urine from one male donor was centrifuged twice to remove all cells from the urine for spiking into female urine. 200 ml of urine from each of six female donors was collected in large bottles and mixed with 25 ml of cell-free male urine immediately after collection. Aliquots of 10 ml urine (female plus male) were mixed with 1.7 ml of reagent. Cell-free DNA was isolated on a QIAsymphony system either immediately after mixing with the reagent (t0) or after 4 days of incubation at room temperature. All samples were processed in duplicate. Real-time PCR for y chromosomal DYS14 DNA was performed from duplicate samples. Results are shown in Figure 8. Discussion
[0263] The results shown in Figure 8 indicate that cell-free DNA is rapidly degraded in unstabilized urine or in urine buffered with PBS. In contrast, cell-free DNA is better preserved in urine stabilized with the reagent according to the invention. Basic pH further improved cell-free DNA stability, as demonstrated by cell-free DNA from male urine spiked into female urine. 5. Example 5 Effect of pH on the preservation of cell-free DNA in urine
[0264] Urine was collected from six donors. Aliquots of 10 ml urine were mixed with 1.7 ml of stabilizing reagents R1, R8 (pH 7), R9 (pH 8), R10 (pH 9), R11, R12 (pH 8), R16, R17 (pH 7), R18 (pH 4) and R19 (pH 3) within 15 min after sampling. The pH of the urine-reagent mixtures was determined either immediately after mixing with the reagents (t0) or after incubation at room temperature for 4 days (t4d) or 7 days (t7d) (Table 2). Table 2: The pH of 10 mL urine samples after addition of 1.7 ml of reagent was determined for six donors immediately (t0) or 4 days (t4d) and, in an embodiment, 7 days (t7d) after addition of each reagent. The mean pH values and standard deviations (SD) are shown. [Table 2-2]
[0265] Aliquots of 10 ml urine were mixed with 1.7 ml PBS or stabilizing reagents R1, R8 (pH 7), R9 (pH 8) and R10 (pH 9) within 15 min after sampling. Cell-free DNA was isolated on a QIAsymphony either immediately after mixing with the reagents (t0) or after incubation at room temperature for 4 days (t4d) or 7 days (t7d). All samples were processed in duplicate. 18S rDNA copy numbers were determined from duplicate samples by real-time PCR in triplicate. Results for the 66 bp fragment are shown in Figure 9 and for the 500 bp fragment in Figure 10.
[0266] While cell-free DNA degrades rapidly in unstabilized, PBS-buffered urine, the total amount of cell-free DNA, which is a small molecule, as well as a large molecule, is preserved in urine stabilized with a reagent according to the invention.
[0267] Aliquots of 10 ml urine were mixed with 1.7 ml of reagents R1, R8 (pH 7), R9 (pH 8) and R10 (pH 9) within 15 min after sampling. Samples were either processed immediately or later stored at room temperature for 7 days. For processing, samples were centrifuged at 1900 × g for 15 min. The supernatant was centrifuged again (1900 × g for 10 min). The cell pellet achieved from the first centrifugation was dissolved in 200 μl of PBS and used for extraction of genomic DNA using the QIAamp Blood Mini kit. gDNA integrity was analyzed by agarose gel electrophoresis (Figure 11). The integrity of gDNA obtained from urine samples stabilized with reagent set at acidic pH (R1) was reduced after 7 days compared to the yield from urine samples stabilized with stabilizing reagents set at neutral (R8 (pH 7)) or basic pH (R9 (pH 8), R10 (pH 9)).
[0268] To analyze the effect of pH on the preservation of cell-free DNA, urine from one male donor was centrifuged twice to remove all cells from the urine for spiking in female urine. 200 ml urine each from four female donors was collected in large bottles and mixed with 25 ml cell-free male urine immediately after collection. Aliquots of 10 ml urine (female plus male) were mixed with 1.7 ml PBS or reagents R1, R8 (pH 7), R9 (pH 8) and R10 (pH 9). Cell-free DNA was isolated on a QIAsymphony system either immediately after mixing with the reagents (t0) or after incubation at room temperature for 4 days (t4d) or 7 days (t7d). All samples were processed in duplicate. Real-time PCR for y-chromosomal DYS14 DNA was performed from duplicate samples (Figure 12).
[0269] To further analyze the effect of pH on the stabilization of exfoliated cells and cell-free DNA in urine samples, reagents with even more acidic pH (R18 (pH 4) and R19 (pH 3)) were applied to urine samples. To achieve this goal, 10 ml aliquots of urine were mixed with 1.7 ml of reagents R16, R12 (pH 8), R17 (pH 7), R18 (pH 4) and R19 (pH 3) within 15 min after sampling. Samples were either processed immediately or stored at room temperature for 4 days. For processing, samples were centrifuged at 1900 × g for 15 min. The supernatant was centrifuged again (1900 × g for 10 min) and the supernatant from the second centrifugation was used for duplicate purification of cell-free DNA on a QIAsymphony. The copy number of 18s rDNA was determined from duplicate samples by real-time PCR in triplicate. The results for the 66 bp fragment are shown in FIG. 14 and the results for the 500 bp fragment are shown in FIG.
[0270] EDTA shows a significant decrease in the 500 bp fragment (approximately 32-fold) but a small increase in the 66 bp fragment (see Figures 14 and 15), indicating that larger fragments are more affected by degradation.
[0271] Reagents set at acidic pH (R16, R18 (pH 4) and R19 (pH 3)) allowed recovery of less genomic DNA from cell pellets after storage compared to stabilization reagents set at neutral or basic pH (see FIG. 11). Furthermore, as shown elsewhere, cell-free DNA is already present in urine at the time of collection and is significantly better preserved at non-acidic pH values as shown by spike-in experiments.
[0272] To further analyze the effect of pH on cell-free DNA preservation, urine from one male donor was centrifuged twice to remove all cells from the urine for spiking in female urine. 200 ml urine from each of six female donors was collected in large bottles and mixed with 25 ml cell-free male urine immediately after collection. Aliquots of 10 ml urine (female plus male) were mixed with 1.7 ml of reagents R16, R12 (pH 8), R17 (pH 7), R18 (pH 4) and R19 (pH 3). Cell-free DNA was isolated on a QIAsymphony system either immediately after mixing with the reagents (t0) or after incubation at room temperature for 4 days (t4d). All samples were processed in duplicate. Real-time PCR for y-chromosomal DYS14 DNA was performed from duplicate samples (Figure 16).
[0273] Cell-free DNA preservation was significantly improved in stabilizing reagents at neutral to basic pH compared to acidic pH. Discussion
[0274] The results show that cell-free DNA degrades more rapidly in urine samples stabilized with reagents set at acidic pH values. Cell-free DNA contained in urine at the time of collection / stabilization is better preserved in urine stabilized with neutral or basic stabilization compositions / reagents according to the present invention. A neutral or basic pH further improves the stabilization of cells contained within the urine sample and improves the yield of genomic DNA that can be obtained from stabilized cells (see also FIG. 11).
[0275] Furthermore, the results in Figures 14 to 16 show that the increase in DNA obtained from cells is advantageously reduced by approximately 15-20 times when stabilization according to the invention is used compared to urine samples that were only stabilized with EDTA. In the EDTA stabilized samples, the overall increase in DNA can be inferred from the observed degradation (Dys 14 - see Figure 16) and increase (18s - see Figures 14 and 15). This is reflected in Table 3 below. [Table 3] 6. Urine Processing Workflow
[0276] The above experiments demonstrate that the stabilization technique of the present invention effectively stabilizes cell-free DNA in urine. It also surprisingly preserves the cytological properties of exfoliated nucleated cells. Thus, these cells can be recovered from the cell pellet after centrifugation of the stabilized urine and used in cytological histology methods. The urinary cells appear to be essentially unaffected and well preserved by this stabilization, which was a rather unexpected observation. In addition to cell-free DNA and urinary cells, high-quality genomic DNA can also be isolated from such stabilized urine samples. Stabilization of urine for transportation and short-term storage is advantageously performed using a vacuum collection container, preferably a tube, containing the stabilization composition, preferably in the form of a solution, according to the third aspect. Preferably, the vacuum receiving container is compatible with common urine collection devices, such as the BD Vacutainer Urine Collection solution (see background). This advantage allows the stabilization technique of the present invention to enable a workflow that allows multi-modality testing using one urine sample.
[0277] An exemplary urine processing workflow starts with the collection of human urine in a collection device (e.g., BD Vacutainer Urine Collection Cup, 120 mL). The collected urine is then transferred into a vacuum receiving device (e.g., a urine stabilizing tube) preferably containing a stabilizing composition according to the present invention. Preferably, this transfer occurs directly from the BD Vacutainer Urine Collection Cup, without the need to open the collection cup and mix urine and reagents in a specific ratio, so as to reduce the risk of handling errors and contamination. A similar direct transfer is possible with the method according to the present invention, for example, when using a vacuum receiving device containing a stabilizing agent, and is advantageous over prior art urine stabilizing devices (such as Streck). Urine can also be collected in any other container or bag, and then transferred using a suitable device (e.g., using a BD Vacutainer Urine Transfer Straw) into a vacuum receiving device containing a stabilizing composition according to the present invention, which effectively stabilizes the urine sample for transportation and storage.
[0278] The stabilizing composition contained in the vacuum collection tube stabilizes nucleated cells in the urine, prevents bacterial growth, and inhibits degradation of cell-free DNA. For DNA purification, the cells in the urine sample are separated, e.g., pelleted by centrifugation. Purification of gDNA from the separated cell sample or cell-free DNA from the cell-depleted supernatant can be performed using established purification methods, e.g., manually using a QIAamp Kit, e.g., QIAamp Mini Kit, QIAamp circulating Nucleic Acid Kit, or QIAamp MinElute ccfDNA Kit, and by purification using a QS PAXgene Blood This can be performed using automated methods such as the ccfDNA or QS DSP DNA Mini kits, and other methods are known in the art.
[0279] Furthermore, the cell pellet or a portion of the cell pellet can be resuspended and centrifuged on a slide, i.e. cytocentrifuged, for conventional cytological staining, for example with Papanicolaou.
[0280] As discussed above, in unstabilized urine, cell-free DNA degrades rapidly, so it is very important to rapidly stabilize the urine sample. The stabilization composition according to the present invention achieves this result. As discussed above, the claimed stabilization composition, which includes a high EDTA concentration and preferably has a pH of at least 7, such as at least 7.2, at least 7.3 or at least 7.5, is very effective in stabilizing urine, and in particular protects cell-free DNA from degradation. As demonstrated herein, good results have also been achieved with a stabilization composition having a pH of at least 8. Furthermore, the inhibition of bacterial growth achieved by the stabilization according to the present invention is very advantageous, since it reduces, among other things, the degradation of cell-free DNA contained in the urine sample. This can be achieved, for example, by using a high concentration of EDTA and / or by including a preservative for inhibiting bacterial growth, such as sodium azide or ProClin.
[0281] According to one embodiment, the process according to the invention comprises the following modules covering the complete pre-analytical urine workflow: - a urine collection device. A suitable example is, for example, the BD Vacutainer Urine Collection Cup, which can receive up to 120 mL of urine. Preferably, this container allows the transfer of urine into a receiving device, for example a vacuum tube, which contains the stabilizing composition according to the invention (without having to open the vacuum tube or the container). The urine collection device may also contain one or more stabilizing agents, for example a chelating agent (preferably EDTA) and / or a preservative to inhibit bacterial growth. Such stabilizing agents are preferably included in a dried form, for example a spray-dried form, in the primary urine collection device, such as a urine cup. - Optionally, a transfer device that allows transfer of urine from a specimen cup or pediatric bag to one or more receiving devices, e.g., vacuum tubes, containing the stabilizing composition without exposure to the specimen. A suitable example is the BD Vacutainer Urine Collection Straw. - a receiving device for receiving collected urine, preferably in the form of a stabilizing composition according to the third aspect, containing a stabilizing agent used according to the invention. The urine sample is stabilized in this receiving device, which is preferably a vacuum tube suitable for drawing a defined amount of urine into the tube. The receiving tube is preferably made of shatter-resistant plastic, which ensures safe transport, storage and centrifugation of the urine sample at room temperature. It preferably also contains a safety cap, which prevents the inside of the tube from spreading around when the stopper is opened. According to one embodiment, a vacuum receiving tube, for example a vacuum plastic BD Vacutainer tube, allows the drawing of 10 ml of urine. Advantageously, commercially available receiving / collecting and transferring devices can be used. The contained stabilizing composition stabilizes the cytological properties of exfoliated nucleated cells in urine, the genomic DNA in the nucleated cells, as well as the cell-free DNA in the urine sample, for transport and preferably short-term storage at room temperature. As discussed above, the stabilization composition according to the present invention may not contain cross-linking agents (e.g., formaldehyde or formaldehyde-releasing agents), and in particular prevents bacterial growth and DNA (i.e., cfDNA) degradation.Furthermore, the stabilization composition according to the present invention allows subsequent cytological analysis of the contained cells.Preferably, the stabilization composition is a liquid stabilization composition, such as a solution.
[0282] After stabilization of the urine sample, the stabilized urine sample may be further processed. According to one embodiment, cells are separated from the stabilized urine sample, resulting in (i) a cell sample and (ii) a cell-depleted supernatant. The resulting cell sample and / or supernatant may be further processed. The workflow may include one or more of the following:
[0283] (aa) Purification of cell-free DNA from cell-depleted or cell-free supernatants, where common methods may be used and commercial kits are available (e.g., QIAamp Circulating Nucleic Acid for manual purification of cfDNA from urine). Kit; QIAamp MinElute ccfDNA Kit for manual purification of cfDNA from urine using centrifugation, and automation on the QIAcube and EZ1; QIAsymphony PAXgene Blood ccfDNA Kit for purification of cfDNA from urine.
[0284] (bb) Purification of genomic DNA from isolated cells. Again, common methods for genomic DNA purification may be used, and such methods are also commercially available (e.g., QIAamp Mini Kit for gDNA purification from urine; QIAsymphony DPS Mini Kit for gDNA purification from urine).
[0285] (cc) Cytological analysis of isolated cells. For example, a preparation of urinary exfoliated cells for cytological analysis may be prepared from the resulting cell pellet.
[0286] The isolated DNA (cell-free DNA and / or gDNA) can be analyzed by analytical methods such as real-time PCR, sequencing (e.g., next-generation sequencing) or other analytical techniques. This workflow for urine collection, stabilization and processing advantageously allows for multi-modality testing on one sample.
Claims
[Claim 1] The invention described in this specification.
Citation Information
Patent Citations
Urine preservative reagent for microfiltration
WO2014151437A1
Preservation of cell-free nucleic acids in biological samples
WO2017201612A1
A novel immunoprobe-based method to assess organ injury status through a biofluid-based cell-free DNA (CFDNA) assay
WO2018035340A1
Stabilisation and isolation of extracellular nucleic acids
WO2013045457A1
Stabilisation and isolation of extracellular nucleic acids
WO2013045458A1
